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MECHANISM OF BAX/BAK ACTIVATION IN APOPTOTIC SIGNALING
Kai Huang Ph.D.
University of Nebraska, 2019
Supervisor: Xu Luo, Ph.D.
The Bcl-2 family proteins, including the anti-apoptotic members, pro-apoptotic effectors
Bax/Bak, and the BH3-only proteins, are key components of the mitochondrial apoptotic
pathway. The BH3-only protein Bid is critical for the mitochondrial pathway of apoptosis after
TRAIL-induced death receptor activation. However, the mechanism of Bid activation during
TRAIL-induced apoptosis is unclear. By putting back wild-type and mutants of Bid in Bid
deficient (Bid KO) and Bid/Bax/Bak TKO colon cancer cells, we demonstrated that cleavage
by caspase 8 and mitochondrial targeting are critical events for Bid activation. One of the
biggest mysteries in apoptosis is how Bax/Bak was activated by BH3-only proteins during
apoptosis. It has been widely accepted that mitochondria-dependent apoptosis initiates
when select BH3-only proteins (direct activators) directly engage and activate Bax/Bak. By
generating knock-out cell lines, we found that the reported direct activators, including Bid,
Bim, Puma, and p53, are not required for Bax/Bak activation during apoptosis once the antiapoptotic Bcl-2 proteins are neutralized. We then looked further into the mechanism of
Bax/Bak activation during apoptosis. Through reconstitution of cells lacking all eight proapoptotic BH3-only proteins, we demonstrate that all BH3-only proteins primarily target the
anti-apoptotic Bcl-2 proteins Bcl-xL/Mcl-1, whose simultaneous suppression enables
membrane-mediated spontaneous activation of Bax/Bak. BH3-only proteins’ apoptotic
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activities correlate with affinities for Bcl-xL/Mcl-1 instead of abilities to directly activate
Bax/Bak. Further, Bid and Bim do not distinguish Bax from Bak or accelerate Bax/Bak
activation following inactivation of Bcl-xL/Mcl-1. Remarkably, death ligand-induced apoptosis
in cells lacking BH3-only proteins and Mcl-1 is fully restored by Bid mutants capable of
neutralizing Bcl-xL, but not direct activation of Bax/Bak. Taken together, our findings provide
a “Membrane-mediated Permissive” model, in which the BH3-only proteins only indirectly
activate Bax/Bak by neutralizing the anti-apoptotic Bcl-2 proteins, and thus allowing Bax/Bak
to undergo unimpeded, spontaneous activation in the mitochondrial outer membrane milieu,
leading to apoptosis initiation.
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INTRODUCTION

Apoptosis

In the human body, most of the cell deaths occur in a regulated manner.1 Morphologically, regulated cell deaths are categorized into three types.

Type I cell death is called apoptosis, which is characterized by shrinkage of the cell,
blebbing of the cytoplasmic membrane, and condensation of the chromatin.2 Apoptosis is
initiated when caspase proteases are activated and caspase cascade is formed.3 Type II cell
death is referred to as autophagic cell death. Autophagic cell death is characterized by the
presence of intracellular vesicles and the engagement of autophagy machinery. Type III cell
death is necrotic cell death, or necrosis, which is characterized by swelling of the cell and
rupture of the plasma membrane, as well as loss of organellar structure.
Of the three types, the signaling pathway of apoptosis is the most well-defined.
Apoptosis is primarily mediated through the intrinsic or the extrinsic pathway in response to
different stimuli in various cell types. Both pathways lead to the activation of a common set
of effector caspases, caspase 3, 6, or 7.4 In the intrinsic pathway, stress signals, e.g., UV
irradiation, serum starvation, DNA damage, etc., elicit discrete intracellular pathways that
converge on the mitochondria, causing the release of cytochrome c and other apoptogenic
proteins. Once in the cytoplasm, cytochrome c triggers the formation of the apoptosome,

2

consisting of cytochrome c, Apaf-1, and pro-caspase 9, and leads to the auto-activation of
caspase 9.5 In the extrinsic pathway, the death ligands, Fas/Apo1/CD95 ligand (FasL) or
Apo2L/TRAIL, bind to their cell surface death receptors Fas/Apo-1/CD95 receptor or death
receptors 4/5 (DR4/5), respectively, and trigger their trimerization.6 The trimerized receptors
then recruit pro-caspase 8 through the adaptor molecule FADD and form a death-induced
signaling complex (DISC), in which caspase 8 becomes auto-activated.7 Once activated,
either caspase 8 or 9, in turn, cleaves and activates the more abundant downstream effector
caspases 3, 6, and 7, initiating the execution stage of apoptosis.8

The Bcl-2 family proteins

Bcl-2 family proteins are key regulators of apoptosis, controlling the mitochondrial
outer membrane permeabilization (MOMP), the critical step for mitochondrial apoptosis.9,10
Since the discovery of Bcl-2 in 198411, which displayed oncogenic effects through protection
against cell death instead of promoting cell proliferation12, different members of the Bcl-2
family proteins have been identified. Consisting of both anti- and pro-apoptotic members, the
Bcl-2 family is characterized by the presence of at least one of the four Bcl-2 homology
domains. The anti-apoptotic Bcl-2 family proteins, including Bcl-2, Bcl-xL, Bcl-w, Mcl-1, and
A1, contain all four BH domains, BH1–4. The pro-apoptotic family members are further
divided into the multi-BH domain proteins, Bax and Bak, and the BH3-only proteins, Bad,
Bim, Bid, Bik, Puma, Hrk, Bmf, and Noxa.13
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Bax and Bak are recognized as the effectors of MOMP, as their simultaneous loss
makes the cells highly resistant to most apoptotic stimuli.14 While the anti-apoptotic Bcl-2
family proteins negatively regulate the activation and activities of Bax/Bak, the BH3-only
proteins are known to either directly or indirectly activate Bax/Bak. In response to different
apoptotic stimuli, different subsets of the BH3-only proteins are transcriptionally or posttranslationally activated, and in turn trigger Bax/Bak activation.15,16 For instance, Puma and
Noxa are upregulated in response to DNA damage13,17,18, and Bad, which is in its
phosphorylated form and is bound by 14-3-3 under normal condition, is dephosphorylated
and activated in response to the absence of growth-factor19. Activated Bax/Bak are
responsible for the formation of putative mitochondrial pores, which allow the release of
cytochrome c and other apoptotic factors.20
The dysregulation of the Bcl-2 family proteins results in abnormalities in embryonic
development and diseases. The deletion of anti-apoptotic Bcl-2 family proteins could lead to
abnormal death of cells and abnormalities or early death of the embryos.21-23 On the other
hand, loss of pro-apoptotic Bcl-2 family proteins, either Bax/Bak or BH3-only proteins, or
overexpression of the anti-apoptotic members, usually results in resistance to apoptotic
stimuli. For example, depletion of Bim in mice makes the lymphocytes resistant to multiple
apoptotic stimuli and increase in number.24,25 Deletion of Puma rendered cells resistant to
DNA damage.26 Overexpression of Bcl-xL can be seen in multiple cancer cell lines and
confer resistance to chemotherapy.12,27-29
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The role of Bid in death receptor-induced apoptosis

The BH3-only protein Bid was discovered by interactive cloning in 1996.30 It was first
considered as a ligand for the membrane-associated Bax, as the Bid mutant that could interact
with Bax, but not Bcl-2, induced apoptosis. Later studies showed that Bid is cleaved by
caspase 8 following the activation of the death receptors located on the cell surface.31,32
Bid is a cytosolic, globular shaped protein primarily composed of eight a-helices, with
two central hydrophobic helices cloaked by the remaining six amphipathic helices.33,34 An
unstructured loop (amino acid residues 42–79) located between helices 2 and 3 was found to
contain recognition sites for several proteases, including caspase 8, caspase 2, caspase 3,
calpain, cathepsin B, granzyme B, etc.31,32,35-42

In select cell types, e.g. hepatocytes and numerous cancer cell lines, the extrinsic
pathway needs to crosstalk with the intrinsic pathway to achieve apoptosis.43 In response to
extracellular death ligands, the engaged death receptors instruct the formation of the DISC
and the activation of caspase 8 in most cells with functional death receptors.44 These death
ligand-responsive cells, however, are classified into Type I and Type II, depending on the
requirement of the mitochondria for apoptosis.45 In type I cells, the classical extrinsic
pathway is in operation, with active caspase 8 directly cleaving and activating the effector
caspases.45 In type II cells, caspase 8 is unable to efficiently cleave and activate caspase 3,
6, or 7, primarily due to the presence of XIAP, a potent inhibitor of active effector caspases,
rendering a halt to the classical extrinsic pathway.46 Yet, this blockade can be bypassed in
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these cells by invoking the help from the intrinsic pathway. Instead of cleaving and activating
caspase 3 in these cells, active caspase 8 is able to cleave Bid,31,32,35 allowing the Cterminal part of Bid, termed truncated Bid (tBid), to move to the mitochondria and directly or
indirectly activate Bax/Bak. Active Bax/Bak then mediates the release of cytochrome c and
Second Mitochondria-derived Activator of caspases (Smac), a highly potent inhibitor of the
XIAP protein, and trigger the formation of the apoptosome.47,48 The engagement of the
mitochondrial pathway through Bid then allows these type II cells to be efficiently killed
following the addition of the death ligands.49 Importantly, most cancer cells are type II cells in
which this hybrid pathway, involving the death receptors, caspase 8, Bid, Bax/Bak, and
caspase 3, is operational in response to the death ligands.50

BH3-induced Bax/Bak activation during apoptosis

Since the discover of Bcl-2 family proteins as apoptosis regulators, multiple theories
have been proposed to explain how pro- and anti-apoptotic members of the Bcl-2 family
control Bax/Bak-mediated MOMP to induce caspase activation and apoptosis.

The observation that Bid bound to Bax and induced apoptosis30 initiated the idea that
Bax is activated by the direct binding of certain BH3-only protein(s). One of the major
models of Bax/Bak activation is called the “direct activation” model (FIGURE 1A), which
categorized the BH3-only proteins into two groups, “sensitizers” and “direct activators”. The
sensitizer BH3-only proteins cannot bind and activate Bax/Bak, but instead bind and
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inactivate the anti-apoptotic members of the Bcl-2 family proteins. The “direct activators”
(e.g. Bid and Bim) are sequestered by anti-apoptotic proteins under normal condition, and
are displaced by “sensitizers” when the cells face apoptotic stimuli. The released tBid or Bim
then directly interact with and activate Bax/Bak.51,52

tBid is the first BH3-only protein that was shown to be able to induce Bax-activation in
a cell-free system. Kuwana et al reported that recombinant tBid or its BH3 peptide can
activate the monomeric Bax and induce the release of large molecules from vesicles
containing cardiolipin that mimic the mitochondrial outer membrane.52 Later studies showed
that Bim also have similar activity.51,53 The interaction between Bim and Bax has also been
shown with NMR study.54 Co-expression of Bad and Noxa (targeting Bcl-xL and Mcl-1,
respectively) can induce apoptosis in WT MEFs cells but not in Puma deficient cells with
Bim knockdown55, in which tBid was also not produced, indicating the requirement of the
direct activators (tBid, Bim, and Puma) for Bax activation. Increasing number of proteins
have been reported to have the ability to directly activate Bax and Bak, including BH3-only
proteins Bik, Bmf, Hrk,56, and Noxa57, and non-Bcl-2 family proteins, such as p5358 and Rb54.

An alternate of the “direct activation” model is called the “neutralization” model
(FIGURE 1B). It claimed that under normal conditions, anti-apoptotic Bcl-2 proteins directly
binds and inhibit Bax/Bak, while the BH3-only proteins, following apoptotic stress, disrupt
this interaction and release the constitutively active Bax/Bak to induce MOMP.59 A “unified
model” attempted to combine both concepts and suggested that the activation of Bax/Bak is
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induced by a transient interaction with “direct activator” BH3-only proteins. The activated
Bax/Bak are sequestered by pro-survival Bcl-2 proteins, which also have interaction with

A

B
Direct
Activator

BH3-only

Sensitizer
BH3(Inactivator)
only

Anti-apoptotic
Bcl-2 proteins

Inactive
Bax/Bak

BH3-only

Anti-apoptotic
Bcl-2 proteins

Active
Bax/Bak

Active
Bax/Bak

Direct Activation

Indirect Activation
(Displacement model)

FIGURE 1 The Indirect (Displacement) and Direct Models of BAX/BAK activation through the
BH3-only proteins. A The Indirect Activation (Displacement) Model of BAX/BAK activation by BH3only proteins. BAX/BAK proteins are constitutively active but are normally sequestered by the
antiapoptotic BCL-2 proteins. During apoptosis, the BH3-only proteins bind to the anti-apoptotic
BCL-2 family proteins, and release the active BAX/BAK molecules. B The Direct Activation Model
of BAX/BAK activation by BH3-only proteins. The BH3-only proteins are classified into the “direct
activators” and “sensitizers”. Sensitizers only bind to and neutralize the anti-apoptotic BCL-2 family
proteins, but not BAX/BAK. The direct activators, on the other hand, not only binds to and neutralize
the anti-apoptotic BCL-2 proteins, but also directly bind to and allosterically activate BAX/BAK. The
anti-apoptotic proteins not only bind to and sequester the active effector proteins BAX/BAK, but also
bind to and block the direct activators from activating BAX/BAK. The direct activator BH3-only
proteins and the anti-apoptotic BCL-2 proteins are therefore mutual inhibitors. During apoptosis,
both groups of BH3-only proteins neutralize the anti-apoptotic BCL-2 proteins, allowing the direct
activators (i.e., BID, BIM, PUMA) to bind to BAX/BAK and trigger their conformational transformation
into active molecules capable of inducing pores on the mitochondrial outer membrane.

BH3-only proteins.
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The “direct activation” model is supported by multiple studies with either isolated
mitochondria or lipid. Recombinant Bax, which was initially inactive monomer, was activated
and oligomerized by the addition of the “direct activator” BH3-only proteins or BH3 peptides
and induced membrane permeabilization.60,61 Also, BH3 peptides interacted with Bax and
triggered a conformational change that leads to Bax dimer formation in the presence of
detergents or lipid membranes.62 Furthermore, structural studies demonstrated the direct
binding of the BH3 peptides of Bim and Bid to the hydrophobic groove of Bax/Bak.63,64

However, these studies relied strongly on in vitro studies with detergents,
membranes, and isolated mitochondria. It is possible that these conditions did not perfectly
reflect the actual situation in the cells. It is also worth mentioning that the number of the
“direct activator” BH3-only proteins has been growing over time, with most of the BH3-only
proteins, except for Bad, being reported to have “direct activation” activity, while the results
of different studies are contradictory to each other, indicating that the Bax/Bak activation
induced by BH3-only proteins in in vitro assay can vary among different conditions.56,57
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CHAPTER 1: THE MECHANISM OF BID ACTIVATION DURING DEATH LIGAND
MEDIATED APOPTOSIS.
* The content of this chapter is derived from the original publication:
J Biol. Chem. 2016 May 27;291(22):11843-51.

Background:

As is described in the introduction, Apoptosis is primarily mediated through the
intrinsic or the extrinsic pathway. Both pathways lead to the activation of caspase 3, 6, or 7.4
The intrinsic pathway works through the activation of Bax/Bak, which induce MOMP and
cytochrome C release. The released cytochrome c causes the formation of the apoptosome,
which induces the activation of caspase 9.5 In the extrinsic pathway, the death ligands bind
to and activate the death receptors, which in turn activate caspase 8. The activated caspase
8 or 9, in turn, cleaves and activates the effector caspases 3, 6, and 7, initiating the
execution stage of apoptosis.8 In certain cell lines (Type II cells), caspase 8 needs the BH3only protein Bid to initiate apoptosis. Following the activation of caspase 8 by death ligands,
caspase 8 cleaves Bid and produces tBid, which moves to the mitochondria and induces
Bax/Bak oligomerization and MOMP to initiate apoptosis.

It is generally accepted that during death receptor-mediated apoptosis, caspase 8
cleaves Bid following residue Asp-60, the C-terminal fragment of Bid then rapidly associates
with the mitochondrial outer membrane, where it triggers Bax/Bak activation.31,32,65 However,
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the cleavage of Bid following Asp-60 surprisingly did not alter the overall structure of Bid33,
suggesting that other event(s), in addition to proteolytic cleavage, is needed to activate Bid.
Despite the well-known requirement of both caspase 8 and Bid in cell surface death
receptor-mediated apoptosis in mouse liver or in most human cancer cells, the requirement
for cleavage of Bid by caspase 8 in death receptor-mediated mitochondrial pathway of
apoptosis has remained unclear. This is because an uncleavable full-length Bid mutant was
found to possess strong apoptotic and cytochrome c releasing activity in vivo and in vitro, in
a process of cell death named anoikis.66 In addition, Bid can also be cleaved by the effector
caspases, caspase 3/6/7, after Asp-60 during apoptosis.67 Thus, whether the cleavage of
Bid after Asp-60 by caspase 8 is responsible for the engagement of the mitochondrial
pathway following death receptor activation in type II cells has remained unclear. Moreover,
as caspase cleavage failed to elicit a conformational change of Bid,33 how Bid becomes
activated remains unknown. In the current study, we generated human colon cancer cells
with loss of Bid or combined loss of Bid, Bax, and Bak, and addressed these critical issues
by putback experiments.

Results:

Loss of Bid blocks TRAIL-induced apoptosis in HCT116 cells.

To investigate the role of Bid and its processing by caspase 8 in death receptor-
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mediated apoptosis in type II cells, we employed genome editing to eliminate the Bid protein
from HCT116 cells. A TALEN expressing plasmid targeting the central region of Bid (exon 4)
was transfected into HCT116 cells together with a reporter plasmid expressing a hygromycin resistance gene. After hygromycin selection, the single clones were isolated and
screened for the loss of Bid protein by Western blot analysis. Two clones, Bid KO clones 1
and 2, with a loss of the Bid protein (FIGURE 2A), were chosen for further analysis by
genomic PCR and sequencing. As shown in FIGURE 2B, both clones have heterozygous
frameshift mutations within the TALEN target region in exon 4 of the Bid gene.
We first examined the HCT116 wild-type and the two Bid KO cells for their response
to TRAIL treatment. Not surprisingly, while full-scale apoptosis was observed in wild-type
HCT116 cells, as judged by PARP cleavage in cell lysates, both Bid KO clones showed little
apoptosis following TRAIL treatment, indicating that HCT116 cells are indeed type II cells
that require Bid and the mitochondrial pathway for apoptosis in response to death ligands
(FIGURE 3). These results also functionally confirmed that Bid is indeed lost from the Bid
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KO cells.

FIGURE 2. Generation of Bid KO HCT116 cells. A whole cell lysates from wild-type and Bid KO
clones 1 and 2 of HCT116 cells were subjected to SDS-PAGE and probed with the indicated
antibodies. B Sequence comparison between wild-type, Bid KO clones 1&2 around the TALEN
target site in exon 4 of human Bid gene. a and b indicate the 2 alleles of Bid gene. The TALEN
target site is underlined in the wild-type Bid sequence.

To eliminate the possibility that the TALEN plasmid used against Bid in this study
might have caused unintended mutations in other genes, which may be responsible for the
observed blockade of apoptosis in the Bid KO cells, we sought to re-introduce wild-type Bid
into these cells and test if it can restore apoptosis. Retrovirus from empty vector or those
expressing wild-type or mutants of Bid were used to infect the HCT116 Bid KO clone 1 cells.
As the retroviral vector used also carries a puromycin resistance gene, we selected the
infected cells with puromycin. The selected pool of Bid KO/vector and Bid KO/Bid were
examined for Bid expression and response to TRAIL. Bid expression was to a large extent,
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restored in HCT116 Bid KO/Bid cells (FIGURE 4A). Following treatment by TRAIL, procaspase 8 was cleaved and presumably activated in w.t., Bid KO, Bid KO/vector, and Bid
KO/Bid HCT116 cells. As expected, TRAIL treatment generated tBid in both wild-type and
Bid KO/Bid cells (FIGURE 4B). Interestingly, while pro-caspase 3 was cleaved, presumably
by caspase 8, to generate p20 in all five Bid KO cell lines, the p17 (large subunit of caspase
3) cleavage product was only found in w.t. and Bid KO/Bid cells. Not surprisingly, apoptosis,
as indicated by PARP cleavage, was restored in Bid KO/Bid cells following TRAIL treatment.
These results indicated that Bid is indeed required for TRAIL-induced apoptosis in HCT116
cells.

Cleavage of Bid at residue Asp-60 and
an intact Bid BH3 domain are required for
TRAIL-induced apoptosis.

FIGURE 3. Loss of Bid blocks TRAIL-

Whereas it is known that Bid can be

induced apoptosis. The wild-type and Bid
KO clones 1 and 2 HCT116 cells were

cleaved following Asp-60 by caspase 835, it has

treated with TRAIL (50 ng/ml) for 4 h
before being harvested. Whole cell lysates

not been established that this cleavage

were generated and subjected to SDSPAGE and Western blot with the indicated

happens at the endogenous level during

antibodies.

TRAIL-induced apoptosis. Further, as fulllength Bid was found to possess strong apoptotic activity66, it is not clear whether the
cleavage has any functional significance in transducing the signal to the mitochondria
through tBid. We sought to address these issues by expressing a Bid mutant that is resistant
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FIGURE 4. Requirement of cleavage at Asp-60 and an intact BH3 domain of Bid in TRAILinduced apoptosis. A Whole cell lysates from w.t. HCT116 and stable pools of Bid KO clone 1
infected with retrovirus produced from empty vector or those expressing wild-type and the indicated
mutants of human Bid were subjected to SDS-PAGE and Western blotting. B The indicated cells were
treated with TRAIL (50 ng/ml) for 4 h. Whole cell lysates were harvested and subjected to SDS-PAGE
and Western blot with the indicated antibodies. C HCT116 w.t. and stable pools of Bid KO
HCT116cells infected with the indicated retroviruses were treated with TRAIL (50 ng/ml) for 4 h before
being stained with Hoechst dye. The percentage of cells that underwent nuclear condensation or
fragmentation was quantified. The results are averages of two independent experiments.

to cleavage by caspase 8 (BidD60E) in the Bid KO cells. First, we established a Dox- inducible
expression system in which cell pools express GFP, Bid, BidD60E (mutation at the caspase
8cleavage site) or BidG94E (inactivating mutation in the BH3 domain) in response to Dox.
Similar to GFP, the wild-type and mutants of Bid failed to induce apoptosis following 8 or 12
h of Dox induction, when their respective levels reached or surpassed the endogenous level
(FIGURE 5). However, Bid and its two mutants showed a mild level of apoptosis after 16 h
of Dox induction, whereas no apoptosis was observed following expression of GFP. These
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results indicate that full length or non-cleavable Bid induces apoptosis only when it is
overexpressed, and such an activity is not dependent on an intact BH3 domain.
Second, we examined the ability of Bid and its mutants to mediate apoptosis following
death receptor activation. Following infection by a retrovirus constitutively expressing Bid,
BidD60E, or BidG94E, the Bid KO cells were selected by puromycin (FIGURE 4A). The resulting
cell pools were then examined for their response to TRAIL treatment. While caspase 8 was
cleaved and presumably activated following the addition of TRAIL, the BidD60E - reconstituted
Bid KO cells failed to produce tBid (FIGURE 4B). Importantly, no apoptosis was observed in
these cells, as demonstrated by a lack of PARP cleavage (FIGURE 4B) and nuclear

FIGURE 5. Apoptotic activities of Bid and its mutants when expressed in Bid KO cells. Bid
KO HCT116 clone 1 cells carrying Dox-inducible expression viruses for GFP, Bid, Bid D60E, or
Bid G94E were treated with Dox (1 µg/ml) for the indicated time. Cells were harvested at the end
of the Dox treatment and assayed for protein expression and PARP cleavage by Western blot.

condensation (FIGURE 4C), indicating that cleavage of Bid at residue Asp-60 is absolutely
required for TRAIL-induced apoptosis in HCT116 cells. These results also indicate that
uncleaved Bid is unable to mediate the death receptor-mediated apoptotic pathway in type II
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cells.
Following cleavage of Bid by caspase 8, cleaved Bid is known to move to the
mitochondria and directly or indirectly activate Bax/Bak. To test if a functional BH3 domain of
Bid is required for TRAIL-induced apoptosis, the mutant BidG94E, carrying an inactivating
mutation in the BH3 domain, was introduced into the Bid KO cells by retrovirus, followed by
puromycin selection. Not surprisingly, while BidG94E was cleaved by caspase 8 following
TRAIL treatment, as indicated by the generation of tBid (BidG94E), no apoptosis was
observed. Consistently, no active caspase 3 or cleaved PARP was observed, indicating that
a functional BH3 domain of Bid is required for TRAIL-induced apoptosis (FIGURE 4B).

An initiator caspase, not effector caspases, cleaves Bid following Asp-60 to
generate tBid.

As Bid can also be cleaved by caspase 3 at Asp-6067, it remains possible that the 15kDa “tBid” normally observed following death receptor activation is the result of cleavage by
the downstream effector caspases (caspases 3/6/7), which are activated by the Bax/Bakdependent mitochondrial pathway of apoptosis4. To block the activation of the downstream
effector caspases and yet allow the initiator caspases to be activated following TRAIL
treatment, we sought to generate cells that are deficient for Bax and Bak under the
background of Bid KO. Bid KO clone 1 cells were therefore transfected with two CRISPR
plasmids, one against Bax and the other against Bak, together with a reporter plasmid
expressing a hygromycin resistance gene. Following selection by hygromycin, a single clone
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with a combined loss of Bid, Bax, and Bak, was isolated based on the disappearance of all
three proteins in Western blot analysis (FIGURE 6) and was named the TKO.
The availability of the TKO cells for the first time allows us to test if an initiator

FIGURE 6. Generation of Bid-/-Bax-/-Bak-/- TKO cells. A diagram of the steps involved in generating
TKO cells. B Western blots of whole cell lysates from the indicated cell lines. C, D sequences of Bax
(C) and Bak (D) of the TKO clone around the CRISPR target sites of human Bax and Bak genes. The
CRISPR target sites are underlined in the wild-type Bax and Bak sequences. Both alleles for Bak are
identical in the TKO cells.

caspase, namely, caspase 8 is sufficient to cleave Bid without the participation of the
effector caspases. We therefore stably expressed Bid/GFP fusion proteins with a GFP fused
to the C terminus of Bid (Bid-GFP) or its cleavage defective mutant (BidD60E-GFP) in the
TKO cells through retroviral infection (FIGURE 7A). Five hours after TRAIL treatment, cells
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were harvested for Western blot analysis against GFP. As shown in FIGURE 6B, Bid-GFP
was cleaved into tBid-GFP, and this cleavage is completely abolished in cells expressing
BidD60E-GFP, indicating that an initiator caspase, namely, caspase 8, but not effector
caspases, is responsible for the cleavage of Bid following activation of the death receptormediated apoptotic pathway.
To further investigate if the tBid-GFP is capable of localizing to the mitochondria, we
observed these cells under fluorescence microscopy following TRAIL treatment. Before
treatment, cells expressing Bid-GFP and cells expressing BidD60E-GFP showed cytosolic
staining. However, five hours after the addition of TRAIL, the majority of cells expressing
Bid-GFP displayed punctate staining that co-localizes with the mitochondria, as shown by
immunostaining with an antibody against TOM20, a mitochondrial outer membrane protein.
In contrast, cells expressing BidD60E-GFP display cytosolic staining following the treatment
(FIGURE 7C). This is the first time that the mitochondrial translocation of cleaved Bid was
observed in live cells following cell surface death receptor activation. These results establish
that the initiator caspases, namely, caspase 8 or 10, are sufficient for cleaving Bid into
cleaved Bid, which then moves to the mitochondria.
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FIGURE 7. TRAIL-induced cleavage of Bid at Asp-60 in the absence of Bax and Bak. A
Western blot of whole cell lysates from the indicated cell lines. B TKO cells stably expressing the
indicated proteins were treated with TRAIL (50 ng/ml) for 5 h. Cells were harvested to generate
whole cell lysates, which were subjected to Western blot analysis with the indicated antibodies. C
Mitochondrial translocation of Bid after the cleavage by caspase 8 following Asp-60. Same cells as
in B were treated with TRAIL for 5 h. After treatment, the cells were fixed and immunostained with
antibody against Tom20, and visualized under a fluorescence microscope.

Mitochondrial Membrane Association Is Required for the Apoptotic Activity of
tBid

One of the surprising findings from the NMR study of full-length Bid in solution was that
the cleavage by caspase 8 did not alter the structure of Bid.33 This counter-intuitive finding
suggests that the proteolytic cleavage of Bid at the loop region is not sufficient to activate Bid.
Then, what activated Bid? After the cleavage event, tBid becomes associated with the outer
mitochondrial membrane. We, therefore, tested the role of membrane association in the
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FIGURE 8. Mitochondrial localization-dependent activity of tBid. The Bid KO HCT116 clone 1
cells were infected with retrovirus expressing the indicated proteins under the control of doxycyclin. A
doxycycline (1 µg/ml) and z-VAD (50 µM) were added to the cells for 5 h to induce the expression of
the indicated proteins without causing apoptosis before the addition of MitoTracker. The cells were
then visualized under a fluorescence microscope. B, same cells as in A were treated with
doxycycline. At the indicated time points after the treatment, cells were harvested. The whole cell
lysates were subjected to Western blot analysis with the indicated antibodies. C, Bid KO HCT116
cells with Dox inducible expression of the indicated proteins were treated with Dox (1 µg/ml). The
cells were stained with Hoechst dye 0, 2, and 3.5 h after doxycyclin treatment. The percentage of
cells that underwent nuclear condensation or fragmentation was quantified. The results are averages
of two independent experiments.

apoptotic activity of tBid. As helices 6 and 7 have been found to be part of the mitochondrial
targeting sequences of tBid,68,69 we generated a tBid mutant that lacks these two helices
(tBidDH6&7). As expected, while wild-type tBid-GFP showed typical mitochondrial staining,
the deletion of both helix 6 and helix 7 resulted in a complete loss of mitochondrial localization
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(FIGURE 8A). Next, we induced the expression of tBidDH6&7-GFP and tBid-GFP to compare
their apoptotic activities. Strikingly, despite an intact BH3 domain, tBidDH6&7 displayed
greatly diminished apoptotic activity as compared with that of the wild-type tBid (FIGURE 8, B
and C). These results strongly suggest that mitochondrial membrane association mediated by
helices 6&7 plays a critical role in activating Bid following its cleavage by caspase 8.

Discussion:

The BH3-only protein Bid has long been considered the molecular link between the
extrinsic and the intrinsic apoptotic pathways in type II cells.31,32 However, the molecular
switch that enables the engagement of the mitochondrial pathway in response to the death
ligands has not been formally defined. This deficiency is partly due to the unavailability of
the type II cancer cells that are deficient for Bid. In this study, through the generation of Bid
KO and Bid/Bax/Bak TKO HCT116 cells, we established a putback experimental system that
allows us to examine the critical elements of the molecular switch in this hybrid pathway.
This system not only allows us to assay for the processing of Bid or its mutants by
endogenous caspase 8, but more importantly also enabled us to observe the functional
consequences (apoptosis) of this processing in response to TRAIL. Our study addressed the
following three questions.
The first question is how tBid is generated. The role of caspase 3 in the generation of
tBid has remained unclear. While activated caspase 3 can directly cleave Bid following Asp6067, it is also possible that activated caspase 3 can cleave and activate caspase 8, which
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can in turn cleave Bid following Asp-60. The latter mechanism then allows caspase 3 to
indirectly cleave Bid through caspase 8. The commonly observed tBid during TRAIL-induced
apoptosis is therefore likely a mixture of cleaved products from caspase 3 and caspase 8.
Considering the fast kinetics of caspase 3 activation following the activation of caspase 8,
there was no definitive proof that Bid can indeed be cleaved by caspase 8 before the
activation of caspase 3. To further complicate the matter, Bid can also be cleaved by other
proteases, including caspase 2, granzyme B, cathepsin B, and calpain, etc., and these
cleavages are all mapped to the loop region, where Asp-60 is located.37-39,41,70
It is therefore essential to determine if activated caspase 8 following DISC formation
is responsible for the generation of tBid in the absence of effector caspases or other
proteases. The generation of Bid/Bax/Bak TKO cells enabled us to examine Bid cleavage in
the absence of the active effector caspases (FIGURE 6). The translocation of tBid-GFP in
the TKO cells following TRAIL treatment strongly suggests that the effector caspases are
not required for the generation of tBid (FIGURE 7). These results for the first time
demonstrated that caspase 8 cleaves Bid in the absence of caspase 3 activation in vivo, and
thus establishing the temporal and functional relationship between caspase 8 and caspase 3
during death receptor-mediated apoptosis.
Second, is Bid cleavage required for death receptor-mediated pathway of apoptosis?
In other words, what is the consequence of this cleavage in vivo? Full-length Bid was found
to be functional in inducing cytochrome c release and apoptosis.66 In addition, during
anoikis, a form of apoptosis induced after detachment from the extracellular matrix, full-
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length Bid was shown to localize to the mitochondria.71 As caspase 8 was found on the
mitochondria, it is possible that caspase 8 cleaves certain mitochondrial proteins, which then
allow the full-length Bid to engage the mitochondria.72 In this scenario, the cleavage of Bid
by caspase 8 will not be necessary for this pathway. However, such a scenario is eliminated
by the finding that wild-type Bid, but not the D60E mutant, was able to restore apoptosis to
the Bid KO cells in response to TRAIL (FIGURE 4C). Also, while BidG94E was cleaved, it
fails to mediate apoptosis (FIGURE 4C). These results establish that the cleavage of Bid
following Asp-60 and a functional BH3 domain in tBid are absolutely necessary for TRAILinduced apoptosis in HCT116 cells.
Third, how is bid activated after its cleavage by caspase 8? Earlier results from in
vitro studies found that after cleavage, the C-terminal part of Bid (tBid) spontaneously
associates with the mitochondria, whereas the N-terminal part remains soluble.32 It is
reasonable to speculate that cleaved Bid, with N- and C-terminal parts still forming a
complex, constantly collides with the OMM during its free diffusion, just as the uncleaved Bid
does. However, due to the lack of a covalent link between N- and C-terminal parts, the Cterminal part (tBid) associates with the membrane permanently, and the N-terminal part then
dissociates from the C-terminal part. In this study, we tested the role of membrane
association in the activity of tBid. We found that the removal of the membrane-targeting
helices, H6 and H7, greatly diminished the apoptotic activity of tBid, despite the presence of
an intact BH3 domain, suggesting that membrane association plays a critical role in
activating tBid (FIGURE 8). How does the membrane activate tBid? It is possible that the N-
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terminal part of Bid functions as an inhibitor of tBid, and therefore the binding to the
membrane after cleavage changes the conformation of tBid, and helps remove the Nterminal inhibitory domain. Further, the membrane association may greatly increase the
local concentration of tBid, allowing it to interact with Bcl-xL, Mcl-1, or Bcl-2. Consistent with
this, a previous study using liposomes demonstrated that membrane association enhanced
the interaction between tBid and Bcl-xL.73 Together, these studies strongly suggest that the
additional event necessary for activating Bid is the spontaneous membrane association of
tBid after caspase 8-mediated Bid cleavage.
To summarize, this study for the first time established that cleavage of Bid by
caspase 8 following Asp-60 and the subsequent outer mitochondrial membrane association
of tBid are two critical events that activate Bid, allowing the engagement of the mitochondrial
pathway during death receptor-mediated apoptosis.
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CHAPTER 2: BAX/BAK ACTIVATION IN THE ABSENSE OF Bid, BIM, PUMA,
AND P53.
* The content of this chapter is derived from the original publication:
Cell Death Dis. 2016 Jun 16;7:e2266.
Jingjing Zhang Ph.D. and Katelyn O’Neil Ph.D. contributed equally to this work.

Background:

Apoptosis has an important role in shaping body structures during development and
maintaining tissue homeostasis in multicellular organisms.74 In response to numerous
extracellular and intracellular apoptotic signals, cells initiate divergent intracellular pathways,
which converge on the mitochondria to trigger mitochondrial outer membrane
permeabilization (MOMP).9 The Bcl-2 family proteins, which include the anti-apoptotic
members (Bcl-2, Bcl-xL, Bcl-w, Mcl-1, and A1), the effector proteins Bax and Bak, and the
pro-apoptotic BH3-only proteins (Bad, Bid, Bik, Bim, Bmf, Hrk, Noxa, and Puma), are major
regulators and effectors of MOMP.13 Whereas the anti-apoptotic members suppress MOMP
by inhibiting the activation and activities of Bax/Bak, the pro-apoptotic BH3-only proteins,
considered the sentinels for the stress signals, promote MOMP by directly or indirectly
activating Bax/Bak.75 Once activated, both Bax and Bak form homo-oligomers on the outer
mitochondrial membrane (OMM), and apparently generate membrane pores, which allow
the escape of apoptogenic proteins, that is, cytochrome C and Smac, from the
intermembrane space, leading to the formation of the apoptosome and the subsequent
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effector caspase activation.5
Bax and Bak are normally globular shaped alpha-helical proteins, both containing a
hydrophobic helix surrounded by eight amphipathic helices.76,77 While Bak homo-dimers
reside on the OMM, Bax is primarily a cytosolic monomeric protein under normal
conditions.76,78 Responding to various apoptotic stimuli, different subsets of BH3-only
proteins become transcriptionally or post-translationally activated (i.e., tBid and Bim).18,25,31,32
These activated BH3-only proteins then trigger dramatic conformational changes in Bax and
Bak, causing Bax to rapidly move to the OMM, where both Bax and Bak coalesce to
generate homo-oligomers necessary for pore formation.9 Conceivably, the transition of Bax
and Bak from harmless proteins to potent killers represents a critical switch in the
mitochondria-dependent apoptotic pathway, and the molecular mechanism of this
conversion has remained a major focus in apoptosis research.79,80
A large number of biochemical and structural studies have uncovered three
interactions among the Bcl-2 family proteins. First, the anti-apoptotic family proteins interact
with active Bax/Bak to inhibit their activity, and the removal of this inhibition is considered a
required step before Bax/Bak activation.81,82 Second, the activated BH3-only proteins
sequester the anti-apoptotic Bcl-2 proteins.83,84 Third, three BH3-only proteins, tBid, Bim,
and Puma, through their BH3 domains, directly bind and activate Bax/Bak.51,54,63,85 On the
basis of these interactions, two major models of Bax/Bak activation have been proposed.
The Indirect Activation model suggests that Bax/Bak are activated through relief of inhibition,
as the BH3-only proteins bind and neutralize all the anti-apoptotic Bcl-2 proteins, which
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otherwise sequester active Bax/ Bak.59,83 However, such a mechanism has difficulty in
explaining the mitochondrial translocation of monomeric Bax during apoptosis. On the other
hand, the Direct Activation model suggests that Bax/Bak are activated by the direct binding
of ‘direct activator’ BH3-only proteins, for example, tBid and Bim, and such activation is
facilitated by sensitizer BH3-only proteins, for example, Bad, which neutralizes anti-apoptotic
Bcl-2 proteins, freeing the direct activators.55 In addition to the BH3-only proteins, the tumor
suppressor p53 has also been found to possess the activity of directly activating Bax.53
Recent studies demonstrated that the DNA binding domain of p53 directly binds to the
hydrophobic groove of Bax, and this interaction was postulated to directly trigger the
conformational changes of Bax needed for its activation.86
Despite compelling data from in vitro studies, the physiological relevance of such a
direct activation mechanism has not been established.87,88 In this study, genetic approaches
were used to investigate the role of the three major direct activator BH3-only proteins Bid, Bim,
and Puma, and the tumor suppressor p53 in Bax/Bak activation during apoptosis.

Results:

The direct activator BH3-only proteins not only possess the ability to directly activate
Bax/Bak but also avidly bind to and neutralize the anti-apoptotic Bcl-2 proteins.89 Thus,
genetic elimination of a direct activator BH3-only protein will result in the simultaneous loss
of both activities. To evaluate the roles of the neutralizing and direct activating activities of
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the direct activators, we used a two-step approach involving the genetic loss of the direct
activators and the genetic or functional ablation of the anti-apoptotic Bcl-2 proteins. First, we
generated cells deficient for all direct activators, effectively eliminating both activities of
these proteins. Second, we restored the neutralizing activity of the direct activators in these
knockout cells with a combination of genetic ablation, siRNA knockdown, and/or specific
inhibitor of the anti-apoptotic Bcl-2 proteins, essentially mimicking the neutralizing activity of
the direct activators in the absence of these proteins. This system allowed us to assess the
contributions of the neutralizing and direct activating activities of the direct activator BH3only proteins in Bax/Bak activation.

Generation of the TKO and PentaKO cell.

To investigate the role of the three commonly recognized direct activator BH3-only
proteins, Bim, Bid (tBid), and Puma, in Bax/Bak activation, a combination of transcription
activator-like effector nucleases (TALEN)90 and CRISPR-Cas991,92 techniques was used to
generate human colon cancer HCT116 cells deficient for all three proteins. First, a TALENexpressing plasmid that targets the first exon of Bim was constructed and introduced into
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HCT116 cells by transient transfection together with a reporter plasmid expressing RFP and
GFP- hygromycin resistance fusion protein (G-HygR) as an indicator for the transient
expression of the transfected TALEN. Following a selection by hygromycin and subsequent
screening by western blot, three Bim-deficient clones were isolated, mixed, and transfected
with two CRISPRexpressing plasmids
(Strategy 1), or two
pairs of Nickase (a
variant of CRISPR)expressing plasmids
(Strategy 2), targeting
the genomic
sequences upstream
from the respective
BH3 domains of Bid
and Puma, separately
(Figure 9A). Following
FIGURE 9. Generation of the TKO and PentaKO HCT116 cells. A
Diagram of the strategy for the generation of Bid−/− Bim−/−Puma−/−
HCT116 cells. B Western blot of the cell lysates from the three TKO
clones. * indicates a non-specific protein. C Diagram of the strategy
for the generation of TKO/Bax−/−Bak−/− (PentaKO) HCT116 cells. D
Whole cell lysates of the indicated cell lines were Western blotted
against the indicated antibodies.

another hygromycin
selection, single
clones from each
strategy were
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screened for the loss of both Bid and Puma proteins. Three clones of Bid-/-Bim-/-Puma-/- triple
knock-out cells (named TKOs), two from strategy 1 and one from strategy 2, were confirmed
by western blot analysis (Figure 9B) and genomic sequencing (Table 3). Similarly, CRISPRexpressing plasmids targeting Bax and Bak, separately, were constructed and introduced
into HCT116 cells to generate Bax-/-Bak-/- double knockout cells (named DKOs, Figure 9B).
We also envisioned that if there is Bid/Bim/Puma-independent apoptosis, it will be
important to test whether it is Bax/ Bak-dependent. We, therefore, set out to generate
Bid/Bim/ Puma/Bax/Bak-deficient cells by gene editing. Cells from the TKO clone A were cotransfected with CRISPR-expressing plasmids targeting Bax and Bak. A clone that lost the
expression of all five proteins was verified by both western blot analysis and genomic
sequencing(Table 3) and was named the PentaKO cells (Figures 9C,D).

TKO cells are resistant to several common apoptotic stimuli.

The three independent clones of the HCT116 TKO cells, along with one of the clones
from the DKO cells, were examined for their response to several common apoptotic stimuli,
including the death receptor ligand TRAIL, the ER stress inducer Thapsigargin (TG), and
serum starvation. Not surprisingly, unlike the wild-type HCT116 cells, both DKO and TKO
cells were highly resistant to all three treatments, as evidenced by the lack of PARP
cleavage (Figure 10A) and Annexin V signals (Figure 10B) following each treatment. These
results demonstrate that the loss of Bid, Bim, and Puma confers resistance to apoptosis
induced by TRAIL, Thapsigargin, and serum starvation in HCT116 cells, consistent with

31

findings from an earlier study in which Bid-/-Bim-/-Puma-/- mouse embryo fibroblasts were
used.93

Suppression of Bcl-xL and Mcl-1 causes Bax/Bak- dependent apoptosis in
the TKO cells.

According to the direct activation model, although all BH3-only proteins can
inactivate/ neutralize anti-apoptotic Bcl-2 members, only tBid, Bim, and Puma have the
additional function of directly engaging and activating Bax/Bak.85 It predicts that Bax/ Bak
activation following neutralization of the anti-apoptotic proteins requires at least one of the

FIGURE 10. Loss of Bid, Bim, and Puma suppresses apoptosis induced by multiple
stimuli. A Wild-type cells and the mutant clones of HCT116 were treated with TRAIL (25
ng/ml) for 5 h or with Thapsigargin (3 μM) for 24 h or serum starved for 48 h. Following each
treatment, cell lysates were western blotted against an anti-PARP antibody. A representative
of three independent experiments is shown. B The indicated cells were treated by the same
apoptotic stimuli as in A, and were stained with Annexin V followed by flow cytometry
analysis. Each data point is mean +/ − S.E.M. from at least three independent experiments

three direct activating BH3-only proteins. In an earlier study, inactivation of both Bcl-xL and
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Mcl-1, mimicked by the simultaneous siRNA knockdown of these two proteins, caused
robust apoptosis in HeLa cells.94 Using the same approach, the wild-type, DKO, and TKO
HCT116 cells were transfected with siRNAs against Bcl-xL and Mcl-1, either singly or in
combination. Surprisingly, the double knockdown of Bcl-xL and Mcl-1 induced robust
apoptosis in both wild-type and TKO cells, but not in DKO or PentaKO cells, indicating that
apoptosis in the TKO cells is dependent on Bax/Bak activation (Figure 11A).
As an alternative way to eliminate/inactivate Mcl-1 and Bcl- xL, we also treated the
cells with a combination of ultraviolet light (UV) and ABT-737, with ABT-737 added immediately following UV treatment. While UV is known to eliminate Mcl-1 efficiently through
rapid, proteasome-mediated degradation,95 ABT-737 is a highly specific BH3 mimetic that
potently inhibits Bcl-xL/Bcl-2 /Bcl-w.96 Although the single treatment by ABT-737 caused
modest amount of apoptosis, the combination treatment resulted in much stronger apoptosis
in both wild-type and TKO cells, as evidenced by the disappearance of the full length PARP
protein and the positive Annexin V staining (Figures 11B and C). Of importance, neither
single nor combinatorial treatments caused apoptosis in DKO or PentaKO cells. Together,
these results indicate that inactivation of both Bcl-xL and Mcl-1 leads to activation of
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Bax/Bak in the absence of the three direct activator BH3-only proteins, Bid, Bim, and Puma.

FIGURE 11. Bax/Bak-dependent apoptosis in the absence of Bid, Bim, and Puma in
HCT116 cells following suppression of Bcl-xL and Mcl-1. A Cell lysates were harvested
following transfection by the indicated siRNA oligos as described in Materials and Methods,
and western blotted with anti-PARP antibody. B Cells were treated with either UV (500 J/M2)
or ABT-737 (2.5 μM) or both. Sixteen hours later, cell lysates were harvested and western
blotted with anti-PARP antibody. C Cells were treated by the combination of UV and ABT737 for 16 h, the same as in B, and were stained with Annexin V followed by flow cytometry
analysis. The results are the mean +/ − S.E.M. of at least three independent experiments.

Suppression of Bcl-xL/Bcl-2/Bcl-w and Mcl-1 activates Bax in the absence of
Bid, Bim, Puma, and Bak.

Under normal conditions, Bax exists in the cytosol as a monomeric and inactive
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protein. Following apoptotic stimulation, Bax moves to the mitochondria and forms homooligomers in the mitochondrial outer membrane.97 The mechanism of this translocation
remains not well defined. To see whether mitochondrial translocation of Bax can be induced
by suppression of the anti-apoptotic members of the Bcl-2 family proteins, we established
PentaKO cell pools that either express GFP or those that express GFP-Bax at the endogenous level, and examined the effect of simultaneous suppression of Bcl-xL and Mcl-1.
However, owing to the slow kinetics of siRNA transfection and UV treatment, it is difficult to
monitor the movement of Bax in these cells. Therefore, we decided to generate Mcl-1deficient cells by gene editing, and subsequently inhibit Bcl-xL/Bcl-2/Bcl-w by ABT-737.
PentaKO cells were transiently transfected with the CRISPR- expressing plasmids against
Mcl-1, and the transfected cells were sorted by flow cytometry. A single clone of PentaKO/
Mcl-1-/- (named HexaKO) cells was isolated and verified by western blot and genomic
sequencing (Figures 12A and B, and Table 2,3).
HexaKO cells stably expressing either GFP or GFP-Bax were generated by retroviral
infection, and subsequently sorted by flow cytometry. The level of GFP-Bax expression in the
resulting pool was comparable with that of the endogenous Bax in wild-type HCT116 cells
(Figure 12C). The addition of ABT-737 resulted in robust apoptosis and homo-oligomerization
as monitored by gel-filtration analysis in the presence of CHAPS98, instead of NP40 which can
induce Bax activation in vitro85, in HexaKO cells expressing GFP-Bax, but not in those
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expressing GFP, indicating that GFP-Bax was functional in these cells (Figures 12D and E).
Importantly, this result indicates that apoptosis in HexaKO cells following neutralization of BclxL/Bcl-2/Bcl-w and Mcl-1 is strictly dependent on GFP-Bax. Not surprisingly, although GFP-

FIGURE 12. ABT-737 induces Bax activation in the absence of Bid, Bim, Puma, Bak, and Mcl1. A Diagram for generating HexaKO cells. B Western blot analysis of the cell lysates from the wildtype and HexaKO cells. * indicates a non-specific protein. C Expression level of GFP, Bax, and
GFP-Bax in the indicated cells. Cell lysates were western blotted against an anti-Bax or anti-GFP
antibody. D HexaKO cells reconstituted with GFP or GFP-Bax were treated with ABT-737 (2.5 μM)
for 6 h. The cell lysates were western blotted with anti-PARP antibody. E HexaKO cells were
treated with ABT-737 (2.5 μM) in the presence of z-VAD (50 μM) for six hours before they were
harvested. z-VAD was added to prevent the protein degradation by apoptosis. These cells were
lysed in buffer A with 2% CHAPS and loaded onto a Superdex 200 column for gel-filtration
analysis. Fractions were western blotted against an anti-GFP antibody. F HexaKO cells were
treated with ABT-737 in the presence of z-VAD for 6 h and then stained with MitoTracker and
photographed using a fluorescence microscope.
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Bax is predominantly cytoplasmic in healthy HexaKO cells, it efficiently moved to the
mitochondria within 6 hours following the addition of ABT-737 (Figure 12F), indicating that
suppression of the anti-apoptotic Bcl-2 family proteins is sufficient to trigger Bax translocation
in the absence of Bid, Bim, Puma, Bak, and Mcl-1.

Neutralization of Bcl-xL and Mcl-1 causes apoptosis in the absence of Bid,
Bim, Puma, and p53.

Results from Figures 11 and 12 suggested that the neutralization function of the BH3only proteins is sufficient for triggering Bax/Bak activation. How are Bax/Bak activated
following inactivation of the anti-apoptotic Bcl-2 proteins? As tumor suppressor p53 has been
shown to engage and activate Bax/Bak in vitro,58,99 it is possible that p53 directly activates
Bax and Bak in the TKO cells following Bcl-xL/Mcl-1 inactivation. Therefore, it is necessary
for us to eliminate p53 from the TKO cells (Figure 13A). Following sorting by flow cytometry,
two clones of TKO/p53-/- (QKO) cells were isolated and validated by western blot and genomic
sequencing (Figure 13B, and Table 2,3). As expected, the QKO cells were highly resistant to
TRAIL, Thapsigargin, and serum starvation (Figure 13C). However, the UV-ABT-737
combinatorial treatment induced robust apoptosis in the QKO cells (Figure 13C). Similar to
TKO cells, the QKO cells underwent robust apoptosis following the double siRNA transfection
against Bcl-xL and Mcl-1 (Figure 13D). Together, these results indicate that endogenous p53
is not involved in Bax/Bak activation in the TKO cells following inactivation of anti-apoptotic
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Bcl-2 proteins.

Discussion:

FIGURE 13. Suppression of Bcl-xL and Mcl-1 causes apoptosis in the absence of Bid, Bim,
Puma, and p53. A Diagram for the generation of Bid/Bim/Puma/p53 QKO cells. B Western blot
analysis of the indicated cell lines. C The indicated cells were treated with TRAIL (25 ng/ml) for 5 h
or with Thapsigargin (3 μM) for 24 h or serum starved for 48 h or treated with combination of UV
(500 J/M2) and ABT-737 (2.5 μM) for 16 h. Following the indicated treatments, cell lysates were
generated for western blot analysis with anti-PARP antibody. D Cells were harvested following
siRNA transfection for western blot analysis with anti-PARP antibody. A representative of three
independent experiments is shown.

At some time point following apoptotic stimulation, Bax and Bak, the two requisite
effectors of MOMP, suddenly turn from inactive monomers (Bax) or dimers (Bak) into lethal
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homo-oligomers on the OMM. What is the immediate trigger for this swift and decisive
transition? The answer to this question has been regarded as the ‘holy grail’ of apoptosis
research.13 The three most potent pro-apoptotic BH3-only proteins, tBid, Bim, and Puma,
and the tumor suppressor p53 have been considered the triggering proteins owing to their
ability to directly bind/activate Bax and Bak in vitro.100 In this study, we used a combinatorial
genetic approach in human colon cancer cells to examine the role of these four proteins in
Bax/Bak activation. Surprisingly, we found that upon suppression of both Bcl-xL and Mcl-1,
Bax/Bak become highly active in the absence of all four proteins, indicating that their direct
activating activities are not necessary for Bax/Bak activation. Consistent with this
conclusion, although a strong interaction was detected between Puma and Bcl-xL, no
interaction was detected between Puma and Bax in HCT116 cells.101 Further, whereas
knock-in mutations of Bax in the homo-oligomerization domain98 abolished Bax-dependent
apoptotic response in HCT116 cells, mutations that disrupt the putative interface between
Bax and the direct activator BH3-only proteins (K21E and D33A) failed to suppress
apoptosis.102 These results appear to be incompatible with the current hypothesis that Bid,
Bim, Puma, and p53 directly activate Bax/Bak during apoptosis.
Mouse embryonic fibroblasts deficient for Bid, Bim, and Puma have been previously
generated and tested for their response to various apoptotic stimuli or overexpression of
BH3-only proteins.59,93 However, partly owing to the presence of p53, it has been difficult to
assess the role of direct activation in vivo. Taking advantage of the TALEN and
CRISPR/Cas9 genome editing technology, we established a cellular system in which all
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three direct activator BH3-only proteins and p53 are eliminated from the same cells. On the
basis of the robust apoptosis observed in the QKO cells following the simultaneous
suppression of Bcl-xL and Mcl-1 (Figure 13), we propose a Linear Model, in which the major
targets of the BH3-only proteins are the anti-apoptotic Bcl-2 proteins, whose primary
function is to block the
transition of Bax/Bak from
inactive to active molecules.
During apoptosis, the
activated BH3-only proteins
neutralize the anti-apoptotic
Bcl-2 proteins, and such a
functional removal of the
Bax/Bak inhibitors then

FIGURE 14. The Linear Model for Bax/Bak activation

allows Bax/Bak to rapidly

during apoptosis. In this model, the primary targets of BH3-

transition into active proteins

to

(Figure 14).

neutralize/inactivate both Bcl-xL and Mcl-1, allowing Bax and

Although this model

only proteins are Bcl-xL and Mcl-1, whose primary function is
suppress

stimulation,

Bax/Bak
the

activation.
activated

Following
BH3-only

apoptotic
proteins

Bak to become activated without the direct activation by BH3only proteins and p53

is mostly consistent with the traditional Indirect Activation Model in that the primary target of
the BH3-only proteins are the anti-apoptotic Bcl-2 family proteins,83 it differs from that model
in that it does not specify a need for pre-formed complexes between Bax/Bak and the antiapoptotic Bcl-2 proteins before the onset of apoptosis. Such a distinction accommodates the
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observation that Bax is normally not on the mitochondria and through not well-understood
mechanisms, the mitochondrially localized Bcl-xL retro-translocates Bax to the cytosol.103
How does the neutralization of Bcl-xL and Mcl-1 activate Bax/ Bak? As none of the
three putative direct activator BH3-only proteins and p53 is required for Bax/Bak activation
following inactivation of Bcl-xL and Mcl-1, how then does inactivation of these inhibitors
activate Bax/Bak? As active Bak has been found to form complexes with the anti-apoptotic
Bcl-2 proteins under normal conditions in some cancer cells, the suppression of Bcl-xL and
Mcl-1 is in theory able to liberate the active Bak.104 Consistent with the indirect model, Bak
was found to be active when anti-apoptotic Bcl-2 proteins were suppressed by siRNA
knockdown or small molecule inhibitors in the absence of one, two, or three proteins from
the three commonly recognized direct activators Bid, Bim, and Puma.105,106 As for Bax,
owing to its cytoplasmic localization, it has been challenging to apply the Indirect Activation
Model to Bax’s activation. Fletcher et al.81 proposed that the Bcl-2-like proteins must capture
the small proportion of Bax molecules with an exposed BH3 domain, and therefore
effectively block the auto-activation mediated through Bax’s own BH3 domain.107
Alternatively, the inactivation of both Bcl-xL and Mcl-1 resulted in a loss of the fascinating
but not well understood the retro-translocation activity, which normally shuttles Bax back to
the cytoplasm.103 A third possibility is that the simultaneous inactivation of Bcl-xL and Mcl-1
causes the release of some positive regulator(s) of Bax/Bak activation.108-110 In addition,
recent data found that some other BH3- only proteins, such as Noxa, Hrk, and Bmf, possess
weaker direct Bax/Bak activation activities in vitro.111 Theoretically, it remains possible that
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one or several of these BH3-only proteins may directly activate Bax/Bak upon release from
Bcl-xL/Mcl-1’s sequestration in the absence of Bid, Bim, and Puma. However, such a
scenario would require a significant revision of the current model for Bax/Bak activation.100
Apoptosis in HCT116 cells following anti-cancer drugs requires only Bax, but not
Bak.112 This differential requirement has been attributed to the selective suppression of Bak
by Mcl-1.113,114 However, it has also been suggested that the direct activator BH3-only
proteins selectively activate Bax or Bak in response to chemotherapeutic agents.114 The
creation of Bid/Bim/Puma TKO, Bid/Bim/Puma/ p53 QKO, and PentaKO/Mcl-1-/- cells
provides useful tools to help resolve the selectivity issue, which is critical in the apoptotic
response in cancer following chemotherapeutic treatments.
In summary, our study for the first time demonstrated that inactivation of the two prosurvival Bcl-2 family proteins, Bcl-xL and Mcl-1, triggers Bax/Bak activation in the absence of
the three direct activator BH3-only proteins, Bid, Bim, Puma, and the tumor suppressor p53.
These data suggest that the direct activation activities of these direct activators are not
essential and that BH3-only protein-mediated neutralization of anti-apoptotic Bcl-2 family
proteins serves as the trigger for Bax/Bak activation during apoptosis. These results also
highlight the importance of the anti-apoptotic Bcl-2 family proteins as primary targets of
therapeutic intervention aimed at potentiating or restoring apoptosis in human cancers, where
Bcl-2, Bcl-xL, or Mcl-1 is often overexpressed.
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CHAPTER 3: BH3-ONLY PROTEINS INDIRECTLY ACTIVATE BAX/BAK DURING
APOPTOSIS.
* The content of this chapter is derived from the original publication:
Cell Res. 2019 Sep 24. Epub ahead of print

Background:

The Bcl-2 family proteins, which include the anti-apoptotic, BH3-only, and Bax/Bak, are
known to play critical roles in apoptosis signaling115. In response to apoptotic stimulation, the
BH3-only proteins suppress the anti-apoptotic Bcl-2 proteins, and mediate the activation of
effector proteins Bax and Bak13. Activated Bax/Bak form homo-oligomers, and permeabilize
the mitochondrial outer membrane (MOM), causing the release of cytochrome c and activation
of caspases5,89.
Following two decades of intensive debate on the mechanism of BH3-only-mediated
Bax/Bak activation, it has been widely accepted that the BH3-only proteins function in a
hierarchy as either “sensitizers” or “direct activators” during apoptosis51,55. In particular, the
direct activators, i.e. Bid, Bim, Puma, etc., not only neutralize the anti-apoptotic Bcl-2 proteins,
but also use their BH3 domains to transiently engage Bax/Bak54,61,63,85, triggering a
conformational transformation of inactive Bax/Bak into active, oligomeric, and pore-forming
molecules79. On the other hand, Bad, a classic sensitizer that lacks the ability to bind and
directly activate Bax/Bak, positively regulates apoptosis by binding to and neutralizing the anti-
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apoptotic Bcl-2 proteins, namely Bcl-2/Bcl-xL/Bcl-w51,55,85, thus facilitating Bax/Bak activation
by the direct activators. Using liposomes and in vitro reconstitution, truncated Bid (tBid) and
Bim have been shown to directly bind and activate Bax/Bak51,52,60,61,114. Importantly, recent
liposome-based studies have demonstrated that most pro-apoptotic BH3-only proteins,
except for Bad, possess such ability56,57,111. These results helped build a consensus that
apoptosis initiates when Bax/Bak are directly and allosterically activated by the direct activator
BH3-only proteins116. However, as the number of reported “direct activator’ BH3-only proteins
has grown to include Noxa, Bmf, Bik, and Hrk56,57,111,117, it has been extremely challenging to
assess the role of “direct activation” during apoptosis initiation.
Other mechanisms of Bax/Bak activation have also been proposed over the years.
Based on results from biochemical binding assays and Bid/Bim Double Knockout (DKO) cells
with a reduced expression of Puma, Willis et al. proposed an Indirect (Displacement)
model59,104, in which Bax/Bak are postulated to be constitutively active but are normally
sequestered by the anti-apoptotic Bcl-2 proteins, and that the BH3-only proteins indirectly
activate Bax/Bak by binding to the anti-apoptotic proteins, and thus releasing the active
Bax/Bak. In another study, using elegant cell biology approaches, Edlich et al. presented data
to suggest that while Bax has a natural tendency to move from the cytoplasm to the
mitochondria, the anti-apoptotic Bcl-2 protein Bcl-xL possesses a retro-translocating activity
that moves Bax from the mitochondria to the cytoplasm103. However, due to the presence of
multiple “direct activators” in any given cell, it remains unclear if direct activation plays a role
in these two alternative mechanisms.
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The generation of OctaKO cells118, which lack all eight known pro-apoptotic BH3-only
proteins, for the first time allows for the examination of any given BH3-only protein or its
mutants for their activities without participation from other BH3-only proteins. Further, using
cells deficient for the entire Bcl-2 family, including the BH3-only, Bax/Bak, and pro-survival
Bcl-2 proteins118, the role of BH3-only proteins after neutralization of the anti-apoptotic Bcl-2
proteins can be investigated. In this study, by reconstituting the BH3-only-deficient and Bcl-2
family-deficient cells, the contribution of “direct activation” in BH3-only-mediated Bax/Bak
activation is directly assessed for the first time.

Results:

Bcl-xL and Mcl-1 as direct targets of BH3-only proteins.

Concurrent elimination or inactivation of Bcl-xL and Mcl-1 has been found necessary
and sufficient for Bax/Bak activation and apoptosis in the absence of all eight pro-apoptotic
BH3-only proteins94,118,119. This led us to hypothesize that neutralization of both Bcl-xL and
Mcl-1 by the BH3-only proteins is sufficient for Bax/Bak activation. This hypothesis is tested
by inducible expression of individual BH3-only proteins as GFP-fusion proteins in the
OctaKO118 cells or their derivatives lacking either Bcl-xL or Mcl-1, and monitoring the
progression of apoptosis through cleavage of PARP (a caspase substrate) and caspase 3
(effector caspase), as well as chromosomal condensation or fragmentation (Hoechst staining).
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Of importance, the use of OctaKO based cells should allow us to analyze the function of the
BH3-only protein of interest without the potential assistance by other BH3-only proteins.
OctaKO, Octa/Mcl-1 KO118, and Octa/Bcl-xL KO (Table 4), and Octa/Bax/Bak KO118 cells were
therefore generated through CRISPR/Cas9, and infected with retrovirus to allow Doxinducible expression of the BH3-only proteins. Following Dox addition, Bad3SA, an active
mutant of Bad mimicking the dephosphorylated form of Bad, efficiently killed the Octa/Mcl-1
KO cells, but failed to induce apoptosis in OctaKO or Octa/Bcl-xL KO cells. On the other hand,
Noxa killed only the Octa/Bcl-xL KO cells, but not the OctaKO or Octa/Mcl-1 KO cells. Of note,
Noxa is difficult to detect due to its extremely short half-life120. In contrast, tBid, Bim, Puma,
Bik, Bmf, and Hrk efficiently induced apoptosis in all three cell lines. As expected, none of the
BH3-only proteins displayed any apoptotic activity in the Octa/Bax/Bak KO cells, indicating a
Bax/Bak dependency of BH3-only protein-induced apoptosis (FIGURE 15). These results
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strongly suggest that Bad and Noxa target Bcl-xL and Mcl-1, respectively, and that tBid, Bim,
Puma, Hrk, Bmf, and Bik target both Bcl-xL and Mcl-1 during apoptotic signaling. This
conclusion is consistent with the differential affinities between BH3-only and anti-apoptotic
Bcl-2 proteins as defined through in vitro binding assays83. As Bad is known to only bind Bcl-

FIGURE 15. All BH3-only proteins can trigger Bax/Bak activation by targeting only BclxL/Mcl-1. A Dox-inducible expression of the BH3-only-GFP-fusion proteins was established in
the listed four parental HCT116 knockout cell lines by puromycin selection. GFP is at the Ntermini of most of the BH3-only proteins except for tBid, whose BH3 domain is at the N-terminus.
Dox (2 μg/mL) was added to each of the selected pools expressing different BH3-only proteins as
indicated. Eight hours after induction, cells were harvested for western blot analysis. The faster
migrating protein species in lane 4 and 5 for the Octa/Bax/Bak KO cells are minor degradation
products of G-Puma and G-Bad3SA. B-D Cells in A were stained with Hoechst dye 8 h after Dox
induction. The percentage of cells that underwent nuclear condensation or fragmentation was
quantified. The results are averages with SEM of three independent experiments.
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2, Bcl-xL, Bcl-w, but not Bax/Bak, the robust apoptotic activity of Bad3SA in Octa/Mcl-1 KO
cells strongly suggests that neutralization of Bcl-xL and Mcl-1 is sufficient for Bax/Bak
activation.
To further examine the role of direct activation in Bax/Bak activation, we sought to
compare the apoptotic kinetics of the two classic direct activators, tBid and Bim, which bind
Bax/Bak, Bcl-xL and Mcl-1, with that of the classic sensitizer, Bad (Bad3SA), which binds BclxL, Bcl-2, and Bcl-w, but not Bax/Bak or Mcl-183, in the absence of other BH3-only proteins.
Since all three proteins bind Bcl-xL, we chose to conduct the kinetics comparison in Octa/Mcl1 KO cells, whose survival is strictly dependent on endogenous Bcl-xL. We reasoned that if
the ability to bind Bax/Bak plays a role in Bax/Bak activation, tBid and Bim should display
faster kinetics as compared to Bad3SA, as the latter is unable to bind Bax/Bak. As shown in
FIGURE 17, however, Bad3SA showed a robust Bax/Bak activation with similar kinetics to
that of tBid and Bim, indicating that tBid and Bim’s putative direct activation activities are not
necessary for Bax/Bak activation, and that such activities do not have discernable effects on
Bax/Bak activation following neutralization of Bcl-xL.
However, it remains possible that the direct activator BH3-only proteins, i.e. Bid and
Bim, use both direct and indirect mechanisms to activate Bax/Bak. To examine the
contribution of direct activation and neutralization-mediated indirect activation in Bax/Bak
activation by tBid or Bim, we replaced the BH3 domains of tBid and Bim with that of Bad
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(FIGURE 16). BadBH3 is known to only bind Bcl-2/Bcl-xL/Bcl-w83, such mutants should retain

FIGURE 16. tBid and Bim mutants used to compare the kinetics of apoptosis. A Diagram
of the listed BH3-only proteins and their BadBH3 mutants. B Partial Amino acid sequences of
Bid (tBid), Bim, their BH3 domain mutants, Bad, and Bad3SA. The BH3 sequences are in color.

the ability to neutralize Bcl-xL, but not Mcl-1, and it is expected to completely lose the ability
of “direct activation”. When tested in Octa/Bcl-xL KO cells, unlike wild-type tBid and Bim,
tBid/BadBH3, Bim/BadBH3, and Bad3SA are unable to induce apoptosis, indicating that the
binding specificities of these tBid and Bim BH3 mutants are indeed converted to that of Bad
(FIGURE17A). In contrast, when expressed in the Octa/Mcl-1 KO cells, both BH3 mutants of
tBid and Bim, as well as Bad3SA displayed apoptotic kinetics indistinguishable from those of
wild-type tBid and Bim (FIGURE 17B and C). As Bad has been widely accepted as a protein
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lacking direct activation activity, and that tBid/BadBH3 was shown to be completely unable to
directly activate Bax in liposome assays56, these results indicate that the putative “direct
activation” activities of these “direct activators” do not contribute to their ability to activate
Bax/Bax.
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FIGURE 17. tBid and Bim cause Bax/Bak-mediated apoptosis by neutralizing anti-apoptotic Bcl-2
proteins. A,B Dox-inducible expression for the listed GFP or GFP-fusion proteins were established in
Octa/Mcl-1 KO and Octa/Bcl-xL KO HCT116 cells. Cells were treated with (A) Dox (2 μg/mL) or (B)
Dox+z-VAD for 3 h and were harvested for western blot analysis. C At the indicated time points after Dox
addition, cells were harvested for western blot analysis. D Cells in C were induced with Dox for the
indicated amount of time. Apo-ONE Caspase substrate/buffer for Caspase 3/7 were added to cells at the
end of the treatment, and the plates were analyzed on a fluorescence microplate reader. The results are
averages with SEM of three independent experiments.
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To more directly monitor Bax activation
induced by the wild-type and mutants of the
above mentioned BH3-only proteins, we
devised a Bax dimerization/oligomerization
assay to monitor the kinetics of Bax dimer
formation, a well-recognized event leading to
Bax activation following apoptotic stimulation.
In this assay, cell extracts are prepared at
different time points after the induction of the
BH3-only

or

Bax

proteins.

Following

incubation with the cross-linker BMH, the cell
FIGURE

18.

BMH

assay

to

monitor

endogenous Bax dimerization. Cells were
treated with Dox and z-VAD for the indicated
amount of time before harvested. Whole cell
lysates were incubated with or without BMH
at room temperature for 1 hour. The reaction
mixtures were then subjected to western blot
analysis. “*” indicates a non-specific protein.

extracts are examined for the formation of
dimers of either the endogenous or induced
Bax by western blot. The 40 kD protein
species is confirmed to be Bax dimers as
Octa/Mcl-1/Bax KO cells failed to generate the

40 kD protein in the BMH assay following tBid induction (FIGURE 18). As shown in FIGURE
19, in Octa/Mcl-1 KO cells, wild-type tBid, Bim, their BadBH3 mutants, and Bad3SA, but not
GFP, displayed almost identical kinetics of endogenous Bax dimer formation and apoptosis,
strongly suggesting that neutralization of the anti-apoptotic Bcl-2 proteins is sufficient for
Bax/Bak activation, and that direct activation by the “direct activators” contributes little, if any,
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to Bax/Bak activation.
Considering the selective binding of Bad and Noxa to Bcl-xL and Mcl-1, respectively83,
we examined the cooperativity of these
two proteins in inducing apoptosis in
the

OctaKO

cells

(FIGURE

20).

Retroviral infection was used to stably
express Noxa or its BH3 defective
mutant NoxaL29E in OctaKO cells. A
Dox-inducible system was generated
for the expression of Bad3SA. As
shown in FIGURE 20, the Dox-induced
expression of Bad3SA induced robust
apoptosis in the presence of Noxa, but
not

NoxaL29E,

suggesting

that

neutralization of both Bcl-xL and Mcl-1
FIGURE 19. tBid and Bim cause Bax dimerization
by neutralizing anti-apoptotic Bcl-2 proteins. Cells
were treated with Dox (2 μg/mL) in the presence of zVAD for the indicated amount of time before being
harvested. Whole cell lysates were incubated with or
without BMH (0.2 mM) at room temperature for 1 h.
The reaction mixtures were then subjected to western
blot analysis.

by individual BH3-only proteins or their
combinations is sufficient to trigger
Bax/Bak activation.
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Bim and Bid activate Bax/Bak without preference for Bax or Bak.

In support of the “Direct Activation” model, data from an in vitro liposome reconstitution
study suggested that the two classic direct activators, tBid and Bim, possess differential
activities towards Bax and Bak, with tBid preferentially activating Bak, and Bim preferentially
activating Bax114. We therefore sought to examine such preferential activation through
reconstitution in the OctaKO derivative cells that are deficient for either Bax or Bak. In addition,
Mcl-1 was eliminated so that Bad can be functionally examined in the reconstitution study
(FIGURE 21A, Table 4). In both Octa/Mcl-1/Bax KO and Octa/Mcl-1/Bak KO cells, we
established the Dox-inducible system for the expression of tBid, Bim, or Bad3SA. Following
Dox addition, all three proteins caused robust apoptosis in both cell lines. As expected, none
of these proteins induced apoptosis in the Octa/Mcl-1/Bax/Bak KO cells (FIGURE 21B and C).
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Importantly, all three proteins displayed similar kinetics of apoptosis in either Bax or Bak
deficient cells (FIGURE 21D).
As the above experiments rely on endogenous Bax or Bak, the relative levels of Bax
and Bak in the cells may affect the kinetics of apoptosis. We therefore reconstituted the
Octa/Bax/Bak KO cells with either GFP-Bax or GFP-Bak at comparable levels (FIGURE 22A).

FIGURE 20. Co-expression of Bad and Noxa is able to induce apoptosis by neutralizing BclxL and Mcl-1. A Stable and Dox-inducible expression of the indicated proteins were established in
the listed knockout cell lines. Four hours after Dox addition, cells were harvested for western blot
analysis. B Cells in A were stained with Hoechst dye 4 h after Dox induction. The percentage of cells
that underwent nuclear condensation or fragmentation was quantified. The results are averages with
SEM of three independent experiments. C Stable and Dox-inducible expression of the indicated
proteins were established in the OctaKO cells. At different time points after the addition of Dox, cells
were harvested for western blot analysis. Representatives from at least two independent experiments
are shown for western blots.

In this setting, tBid and Bim also displayed similar apoptotic kinetics (FIGURE 22). These
results are inconsistent with the notion that tBid and Bim preferentially activate Bak or Bax,

55

FIGURE 21. Bim, tBid, and Bad do not distinguish endogenous Bax from Bak. a Generation of
Octa/Mcl-1/Bax KO and Octa/Mcl-1/Bak KO cells. Whole cell lysates for the indicated cells were
analyzed by western blot analysis. b Dox-inducible expression for the indicated proteins was
established in Octa/Mcl-1/Bax/Bak KO, Octa/Mcl-1/Bax KO, and Octa/Mcl-1/Bak KO cells. Four
hours after Dox (2 μg/mL) addition, cells were harvested for western blot analysis. c Cells were
treated the same way as in b and were stained with Hoechst dye after induction. The percentage of
cells that underwent nuclear condensation or fragmentation was quantified. The results are averages
with SEM of three independent experiments. d The Octa/Mcl-1/Bax KO and Octa/Mcl-1/Bak KO cells
with the Dox-induced expression of the indicated proteins were harvested at different time points
following the addition of Dox for western blot analysis.

respectively114. Using Bid chimeric proteins in liposome assays, Hockings et al. was also not
able to observe a preference for Bax or Bak by the BH3 domains56. Together, these results
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support the notion that tBid and Bim’s primary targets are the anti-apoptotic Bcl-2 family
proteins, whose neutralization is sufficient to allow spontaneous Bax/Bak activation.

FIGURE 22. tBid and Bim do not distinguish stably expressed G-Bax from G-Bak. a Doxinducible expression of the indicated proteins was established in Octa/Bax/Bak KO cells stably
expressing comparable amounts of G-Bax or G-Bak. Four hours after induction, cells were harvested
for western blot analysis. b Cells were treated the same way as in a and then stained with Hoechst
dye. The percentage of cells that underwent nuclear condensation or fragmentation was quantified.
The results are averages with SEM of three independent experiments. c Cells in a were harvested at
the indicated time points after Dox addition for western blot analysis. Representatives from at least
two independent experiments are shown for western blots.

Role of BH3-only proteins after neutralization of the anti-apoptotic Bcl-2
proteins.

Although the above results suggest that direct activation activity is not necessary for
Bax/Bak activation, it remains possible that after neutralizing the anti-apoptotic Bcl-2 proteins,
the direct activators interact with free Bax/Bak, and accelerate their membrane-mediated
spontaneous activation. We therefore sought to examine the role of BH3-only proteins in
activating Bax under the cellular background where all anti-apoptotic Bcl-2 proteins are
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FIGURE 23. Endogenous BH3-only proteins do not accelerate Bax activation in the
absence of anti-apoptotic proteins. a Bax/Bak/Bcl-xL/Bcl-2/Bcl-w/Mcl-1/A1 KO cells, which are
named “2+5” cells, were generated with CRISPR/Cas9. Whole cell lysates were examined for the
expression of the indicated proteins by western blot. b Dox-inducible expression of G-Bax or GBaxΔTM was established. At the indicated time points, cells were harvested for western blot. c
Cells were treated with Dox in the presence of z-VAD for the indicated amount of time before
harvested. Whole cell lysates were incubated with or without BMH (0.2mM) at room temperature
for 1 hour. The reaction mixtures were then subjected to western blot analysis. “*” indicates a
non-specific protein.

eliminated. To achieve this, we used CRISPR/Cas9 to generate “2+5” cells, which are
deficient for Bax/Bak and all five major anti-apoptotic Bcl-2 family proteins (FIGURE 23A,

58

Table 4). The lack of anti-apoptotic Bcl-2 proteins is expected to render most of the BH3-only
proteins constitutively active. A Dox-inducible system for the inducible expression of G-Bax
was established in both the “2+5” cells and the Bcl-2 allKO cells, which are deficient for the
17 Bcl-2 family members, including the BH3-only proteins, Bax, Bak, and the five antiapoptotic Bcl-2 proteins 118. As shown in FIGURE 23B and C, the kinetics of Dox-induced Bax
activation (dimer formation) and apoptosis, as measured in the BMH assay and by PARP
cleavage, are similar in both Bcl-2 allKO and “2+5” cells, indicating that the endogenous BH3only proteins do not contribute to Bax/Bak activation in the absence of the anti-apoptotic Bcl-

FIGURE 24. tBid does not accelerate Bax activation in “2+5” cells. A The indicated cells
were treated with TRAIL (25 ng/ml) for 3 hours before they were harvested for western blot. “*”
indicates a non-specific protein. Long exposure of Bid western was displayed to shown tBid. B
Three hours after TRAIL treatment, Dox was added to the indicated cell lines with the Doxinducible expression of either G-Bax or G-BaxΔTM. Cells were harvested at different time points
after addition of Dox for western blot.

2 proteins. This spontaneous activation is entirely mediated by mitochondrial membrane
association, as G-BaxΔTM completely lost the capacity to induce apoptosis in either “2+5” or
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Bcl-2 allKO cells (FIGURE 23B and C). Further, we treated both cells with the death ligand
TRAIL, generating tBid through the death receptor pathway in the “2+5” cells (FIGURE 24A).
Similarly, the presence of tBid in the “2+5” cells did not accelerate the Dox-induced
spontaneous Bax activation, which is completely abolished for the Bax mutant that lacks the
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anti-apoptotic Bcl-2 proteins, the only
target of the ectopically expressed BH3-only proteins is Dox-induced Bax according to the
“Direct Activation” model. In the absence of Bcl-xL, Dox induced GFP-Bax and its
spontaneous activation caused apoptosis with similar kinetics in cells expressing GFP, tBidGFP, G-Bim, or G-Bad3SA. On the other hand, in the presence of Bcl-xL, Dox-induced G-Bax
failed to spontaneously activate in the Bcl-2 allKO cells, indicating that Bcl-xL is capable of
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FIGURE 26. Put-back BH3-only proteins do not accelerate Bax activation in the absence of
anti-apoptotic proteins. A Dox-inducible expression system for G-Bax was established in Bcl-2
allKO cells expressing the indicated BH3-only proteins as GFP chimeras with or without the stable
expression of Bcl-xL. Dox (2 µg/ml) was added in the presence or absence of z-VAD (40 µM) for 2
hours before the cells were harvested for western blot. B Cells in A were stained by Hoechst dye 2
hours after Dox induction. The percentage of cells that underwent nuclear condensation or
fragmentation was quantified. The results are averages with SEM of three independent
experiments. C At the indicated time points following the addition of Dox, cells from A with the
expression of the indicated proteins were harvested for western blot with PARP antibody. D Cells
were treated with Dox in the presence of z-VAD for the indicated amount of time before harvested.
Whole cell lysates were incubated with or without BMH at room temperature for 1 hour. The
reaction mixtures were then subjected to western blot analysis. Arrow indicates the band of tBid-G.
Representatives from at least two independent experiments are shown for western blots. “*”
indicates a non-specific protein.

inhibiting spontaneous Bax activation (FIGURE 26). However, the expression of tBid-GFP, G-
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Bim or G-Bad3SA completely overcame such inhibition, indicating that the expressed tBid,
Bim, and Bad3SA are indeed active (FIGURE 26). These results strongly suggest that the
main function of the BH3-only proteins is to suppress the anti-apoptotic Bcl-2 proteins, whose
function is to suppress the spontaneous activation of Bax/Bak. Thus, once the anti-apoptotic
Bcl-2 proteins are neutralized, Bax undergoes mitochondrial outer membrane-mediated
activation without the need for the BH3-only proteins.

Reconstitution of death receptor-mediated, mitochondria-dependent

FIGURE 27. Put-back of Bid and Bid mutants. A Diagram of Bid and its mutants. B Stable
expression of Bid and its mutants in OctaKO and Octa/Mcl-1 KO cells following retroviral
infection and flow cytometry sorting.

apoptosis pathway by Bid or its mutants.

To examine the role of “direct activation” activity of direct activator BH3-only proteins
during apoptotic signaling, we resorted to the cell surface death receptor-mediated pathway.
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Following death receptor-mediated caspase 8 activation, Bid is cleaved by caspase 8 to give
rise to tBid, which then moves to the mitochondria to cause Bax/Bak activation31,32. We
therefore reconstituted the OctaKO and Octa/Mcl-1 KO cells with endogenous levels of wildtype Bid or several of its mutants with altered BH3 domains through retroviral expression
(FIGURE 27A and B). The first mutant, BidI82A/I83A, was found to be defective in direct activation
in an in vitro liposome assay63. A second mutant, Bid/BadBH3, has its BH3 domain replaced
by that of the sensitizer protein Bad56. BidG94E, a BH3 mutant known to be defective in binding
to Bcl-2/Bcl-xL32, was used as a negative control As expected, while cells reconstituted with
GFP or BidG94E failed to undergo apoptosis in response to TRAIL, expression of wild-type Bid
restored apoptosis, indicating the requirement of a functional Bid in this pathway (FIGURE
28). Remarkably, expression of BidI82A/I83A also fully restored apoptosis in response to TRAIL
in both OctaKO and Octa/Mcl-1 KO cells (FIGURE 28). In contrast, Bid/BadBH3 failed to
restore apoptosis in OctaKO cells (FIGURE 28A, B, D and E). However, such failure appears
to be due to Bid/BadBH3’s inability to bind to and neutralize endogenous Mcl-1, as addition of
S63845121, a highly selective Mcl-1 inhibitor, to OctaKO cells restored the response to TRAIL
(FIGURE 28A and B). Consistently, Bid/BadBH3 completely restored apoptosis to Octa/Mcl1 KO cells in response to TRAIL treatment (FIGURE 28A, C, D and F). Thus, TRAIL-mediated
apoptosis pathway can be fully reconstituted by Bid mutants capable of neutralizing the antiapoptotic Bcl-2 proteins but defective in direct activation, strongly suggesting that death
ligand-induced, Bax/Bak-dependent apoptotic pathway is mediated by the neutralization
activity of the BH3-only protein Bid against Bcl-xL and Mcl-1, following Bid’s activation by
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FIGURE 28. Reconstitution of the death receptor-mediated, Bax/Bak-dependent apoptosis
pathway with Bid and its direct activation-defective mutants in BH3-only-deficient cells.

caspase 8-mediated cleavage and association with the mitochondrial outer membrane
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(FIGURE 29)122.
Continued FIGURE 28. A The indicated stable cell pools were treated with TRAIL (25 ng/ml) in the
presence or absence of S63845 (1 µM), for 2.5 hours and then harvested for western blot analysis.
B, C Cells in A were stained by Hoechst dye 2.5 hours after Dox induction. The percentage of cells
that underwent nuclear condensation or fragmentation was quantified. The results are averages with
SEM of three independent experiments. D The indicated stable cell pools were treated with TRAIL
(25 ng/ml) for the indicated amounts of time and then harvested for western blot. E, F Cells were
treated with TRAIL (25ng/ml) for the indicated amount of time. Apo-ONE Caspase substrate/buffer
for Caspase 3/7 was added to cells at the end of the treatments, and the plates were analyzed on a
fluorescence microplate reader. The results are averages with SEM of three independent
experiments.
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direct BH3-only-Bax/Bak interaction is the trigger or
catalyst for Bax/Bak activation82,97,123. Due to the large number of BH3-only proteins with
overlapping functions, the physiological significance of this model has been difficult to
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assess87. The current study eliminated the possibility of assistance from other BH3-only
proteins, and directly addressed the functional contribution of the “direct activation” activity of
select BH3-only proteins during apoptosis.
Bim and tBid, two most recognized “direct activators”, and Bad, a classic “sensitizer”,
are functionally compared for the first time in BH3-only-deficient cells that also lack Mcl-1
(Octa/Mcl-1 KO) (Figs. 15-26). Such comparison provides answers to two important questions.
First, is neutralization of anti-apoptotic Bcl-2 proteins sufficient for Bax/Bak activation? Second,
what are the contributions of neutralization and direct activation, two separate activities, to the
ability of a direct activator BH3-only protein to activate Bax/Bak? Especially, the requirement
of tBid’s direct activation activity was examined in the context of TRAIL-induced apoptosis
(FIGURE 28). To our surprise, under simplified genetic backgrounds, the “sensitizers” (i.e.,
Bad) and the direct activation-incompetent mutants of “direct activators” (i.e., tBid/BadBH3)
displayed apoptotic activities indistinguishable from those of the “direct activators”, strongly
suggesting that the putative “direct activation” activity does not contribute to Bax/Bak
activation, and that the neutralization activity of BH3-only proteins is sufficient. Although it
remains possible that some BH3-only proteins transiently bind free Bax or Bak as suggested
by results from the in vitro studies, data obtained from anti-apoptotic Bcl-2 deficient cells (Figs.
23-26) suggests that such interactions are non-essential, and unlikely to serve a functional
role in Bax/Bak activation. On the other hand, the free diffusion-based, spontaneous, and
high-affinity binding of Bax/Bak to the MOM, most likely the lipids in the MOM, is required and
sufficient for Bax/Bak activation (FIGURE 26). Consistent with an active role of the lipids in
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Bax/Bak activation, it has been shown that Bax/Bak are efficiently activated by non-ionic
detergents in vitro77,78.
The current study for the first time unequivocally defined the functional relationships
among the Bcl-2 family proteins. Unlike the “Direct Activation” or “Unified” models51,57,82, which
suggest that BH3-only proteins and anti-apoptotic Bcl-2 proteins are mutual inhibitors, our
data clearly suggests unidirectional relationships in which the BH3-only proteins inhibit antiapoptotic Bcl-2 proteins, whose major function is to inhibit membrane-mediated Bax/Bak
activation (FIGURE 30). This conclusion is consistent with the original “Indirect Activation/
Displacement” model in which BH3-only proteins inactivate anti-apoptotic Bcl-2 proteins but
do not directly bind/activate Bax/Bak59. However, key differences exist. The latter model relies
on the notion that Bax/Bak are constitutively active but are sequestered by the anti-apoptotic
Bcl-2 proteins before apoptosis, and therefore suggests that the BH3-only proteins initiate
apoptosis by binding the anti-apoptotic Bcl-2 proteins, thus displacing and releasing active
Bax/Bak81,104. Such a scenario has difficulty explaining the apparent differential localization of
Bax and Bcl-2/xL proteins in healthy cells. In contrast, in combination with results from a
previous study118, our data strongly supports a novel “Membrane-mediated permissive” model
(FIGURE 30), which suggests that the vast majority, if not all, of Bax/Bak molecules exists as
inactive monomers (Bax) or homo-dimers (Bak) before apoptosis63,77, but is uniformly
activated through their spontaneous, free diffusion-driven association with the MOM, once the
anti-apoptotic Bcl-2 proteins are neutralized by the BH3-only proteins or the BH3 mimetics96,121
during apoptosis initiation (FIGURE 30). Consistent with this model, Greaves et al.
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demonstrated that pharmacological inhibition of Bcl-xL and Mcl-1 efficiently induces apoptosis
in the absence of the BH3-only proteins124. Also, the observation that Bax has a natural
tendency of translocating to the mitochondria, but can be retro-translocated back into the
cytosol by Bcl-xL is highly consistent with this model103.
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FIGURE 30. A new model of Bax/Bak activation during apoptosis. A BH3-only-mediated
Bax/Bak activation during mitochondria-dependent apoptotic signaling. In response to apoptotic
signals, select groups of BH3-only proteins become activated, and the activated BH3-only proteins
neutralize the anti-apoptotic Bcl-2 proteins, allowing the free diffusion-driven, membrane-mediated,
spontaneous activation of Bax/Bak through the mitochondrial outer membrane. While Noxa binds
only Mcl-1 and A1, and Bad binds only Bcl-xL, Bcl-2, and Bcl-w, Bid, Bim, Puma, Hrk, Bmf, and Bik
are able to bind all the anti-apoptotic Bcl-2 proteins. B A mitochondrial outer membrane-mediated
permissive model of Bax/Bak activation. Bax/Bak are normally inactive monomers or dimers in
healthy cells. During apoptosis, activated BH3-only proteins bind to and neutralize the anti-apoptotic
Bcl-2 family proteins on the mitochondrial outer membrane, which then provides a permissive
environment for the spontaneous activation of Bax/Bak, culminating in their homo-oligomerization
and the formation of cytochrome c releasing pores.

Overall, our results strongly support the notion that the BH3-only proteins activate
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Bax/Bak primarily by targeting and neutralizing the anti-apoptotic Bcl-2 proteins, therefore
allowing Bax/Bak’s spontaneous activation in the mitochondrial outer membrane118. This new
model of Bax/Bak activation, therefore, largely excludes any role of direct activation by the
“direct activator” BH3-only proteins once the anti-apoptotic Bcl-2 proteins are neutralized. In
other words, the “direct activator” BH3-only proteins (Bid, Bim, etc.) are similar to the
“sensitizers” (i.e. Bad) in that their only function is to neutralize the anti-apoptotic Bcl-2
proteins.
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Chapter 4. material and methods.

Cell culture.

HCT116 cells (ATCC) were cultured in McCoy’s 5A medium with penicillin/
streptomycin and 10% fetal bovine serum (Atlanta Biologicals, #S11150). 293GP cells and
293T cells were grown in DMEM media with penicillin/streptomycin and 10% FBS. All cells
were maintained at 37°C with 5% CO2.

Reagents.

Doxycycline Hydrochloride was purchased from Fisher Scientific. Human recombinant
TRAIL was generated as previously described125.

z-VAD-FMK was purchased from MP

Biomedicals. S63845 was purchased from ChemieTek (IN, USA). Antibodies used include
anti-PARP (Cell Signaling Technologies, no.9524), anti-GFP (Santa Cruz Biotechnology, no
sc-459), anti-Flag (Sigma-Aldrich, no. F1804), anti-Bcl-xL (Santa Cruz Biotechnology, Sc8392), anti-Bcl-2 (Santa Cruz Biotechnology, no sc-509), anti-Mcl-1 (Santa Cruz
Biotechnology, no. sc-819), anti-Bim (Calbiochem, #202000), anti-Bid (Luo et al. 1998), antiBax (Cell Signaling Technologies no. 2772), anti-Bak (Santa Cruz Biotechnology, no. sc-832),
anti-Bcl-w (Cell Signaling Technologies, no. 2724), anti-Bad (Santa Cruz Biotechnology, no.
sc-8044), anti-Noxa (Santa Cruz Biotechnology, no. sc-56169) anti-TetR (Clonetech, no.
631131), CASPASE 8 (Cell Signaling Technologies, no. 9746), anti-CASPASE 3 (Cell
Signaling Technologies, no.9665S) and anti-β-actin (Sigma-Aldrich, no. A5441).
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Immunoblotting.

Cells were harvested and lysed in EBC buffer (120 mM NaCl, 50 mM Tris, 1 mM EDTA,
0.5% NP40, pH=7.5) with protease inhibitors (5 mg/ml pepstatin A, 10 mg/ml leupeptin) and
0.1 mM PMSF. After rotating for 1-2 hours at 4°C and centrifugation at 22,000 g for 10 minutes
at 4°C, supernatant was collected as the whole cell lysate.

Protein concentrations were

measured by Coommassie Protein Assay solution (Thermo Scientific, # 1856209).

Cell

lysate was mixed with 4X SDS loading buffer and heated at 98°C for 5 minutes before resolved
by SDS-PAGE gel and transferred onto a nitrocellulose membrane, which was then incubated
with primary and secondary antibodies for western blotting.

Proteins of interest were

detected with Chemiluminescence.

Plasmids.

A TALEN expression vector for Bid was designed and constructed by Seoul National
University, TALEN Library Resource, order H156033. Human Bid cDNA was PCR amplified
and ligated into XhoI- and EcoRI-digested pEGFP-C3 (Clontech, 6082-1) vector to generate
GFC3-Bid (N-terminally tagged with GFP). Standard site-directed mutagenesis was
performed on GFC3-Bid plasmid to generate BidD60E and BidG94E mutants. The wild-type and
mutants of Bid were then cut out of the EGFP-C3 vector by XhoI and EcoRI and ligated into
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the XhoI/EcoRI cut retroviral expression vector plasmid pMSCV-PIG (Addgene, plasmid
21654). To construct the CRISPR expression plasmids against Bax and Bak, two pairs of DNA
oligos designed for sgRNA targeting the specific site of Bax and Bak were annealed and then
ligated into Bbs1 digested px330 vector (Addgene #42230). The wild-type and BidD60E mutant
of Bid were cut out of the EGFP-C3 vector by XhoI and EcoRI and ligated into the XhoI/EcoRI
cut EGFP-N2 vector to generate GFN2-Bid and GFN2-BidD60E (C-terminally tagged with
GFP). Bid-GFP and BidD60E-GFP were then PCR amplified and ligated into XhoI and HindIII
digested retroviral MSCV-IRES-GFP vector. The tBid-DH6&7 was generated using the PCR
“gene SOEing” method.126 Wild-type and mutant tBid-GFP was PCR amplified from the GFN2
constructs and ligated into NotI and BamHI cut inducible retroviral expression vector plasmid
pRetroX-Tight-Pur. The GFP, wt Bid and the BidD60E and BidG94E mutants were PCR amplified
and ligated into NotI and EcoRI digested inducible retroviral expression vector plasmid
pRetroX-Tight-Pur.CRISPR plasmids used were generated as described before118.
The retroviral vector pRxXE-9HG was generated by ligating a fragment containing
9His-GFP and XhoI cut site into the retroviral vector pRetroX-Tight-Pur vector (Clonetech)
and site directed mutagenesis to disable the XhoI site preexisted in the vector. Human tBid,
Bim, Puma, Bik, Bmf, Hrk, Noxa, and mouse Bad3SA were cut from respective pEGFP-C3
constructs and ligated into the pRxXE-9HG vector with XhoI and EcoRI sites.
Bim, Bid, and tBid mutant with BH3 domain replaced with Bad BH3 (Bim/BadBH3,
Bid/BadBH3, and tBid/BadBH3) was generated by PCR SOEing. Human Bim R143-Y162 and
human Bid D81- S100 were replaced by human Bad W105- S124. The cDNA for Bim/BadBH3
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was cloned into pRxXE-9HG vector with XhoI and EcoRI sites. The cDNA for tBid-GFP or
tBid/BadBH3-GFP was cloned into pRetroX-Tight-Pur vector with NotI and EcoRI sites. The
retroviral expression plasmids pMIG-GFP and pMIG-GFP-Bax were constructed using XhoI
and HindIII cut sites to ligate DNA fragments containing GFP or GFP-Bax89 into the
XhoI/HindIII-digested MSCV-IRES-GFP (pMIG) vector.
The retroviral expression plasmids pMIG-GFP and pMIG-Bcl-xL were generated as
described before

118

. Flag-Noxa and Flag-Noxa L29E was PCR amplified from respective

pcFlag constructs and cloned into MSCV-IRES-GFP (pMIG) vector using XhoI and Hind3 sites.
GFP-Bax, GFP-Bak, GFP-Bim, tBid-GFP and GFP-Bad3SA was PCR amplified from
respective pEGFP-C3 or pEGFP-N2 constructs and cloned into MSCV-IRES-GFP (pMIG)
vector using EcoRI and Hind3 sites. Tetracycline repressor gene was PCR amplified from
pRetroX-Tet-on Advanced plasmid and cloned into mpMIG (modified pMIG) using XhoI and
EcoRI sites. GFP-Bax and GFP-BaxΔTM was PCR amplified and cloned into lentiviral vector
pCW57.1 (Addgene #41393) with EcoRI and MluI sites. BidI82A/I83A and BidG94E were generated
by standard site directed mutagenesis. Bid, Bid/BadBH3, BidI82A/I83A and BidG94E were cloned
into mpMIG (modified from pMIG) vector with XhoI and EcoRI sites.

Plasmid Transfection.

FugeneHD reagent (Promega, E2311) was used for transfection in HCT116 cells
according to the manufacturer's instructions. For CRISPR transfection, cells were seeded in
a 35 mm plate at the density of 3-4 x105 cells per plate 24 hours prior to transfections. 500
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ng of each CRISPR plasmid was co-transfected with 300 ng of the corresponding mRFPTS-2A-HYG-EGFP reporter plasmid. pcDNA3.1 was added to make the total DNA
concentration of 1.8 µg per transfection. 24 hours after transfection, the transfected cells
were split 1:2 and went on to flow cytometry sorting for GFP/RFP positive cells or
Hygromycin B (1 mg/ml, Calbiochem, #400050) selection. The sorted or selected cells
were plated for single clones in 15 cm plates.

Flow cytometry.

BD FACSAria or a BD FACSAria II cell sorter with BD FACSDiva 6.1.2 software (UNMC,
Flow Cytometry Research Facility) were used to sort transfected and infected cell lines
according to GFP or RFP protein expression. Sorted cells were then collected for plating
based on detection of GFP and/or RFP signals.

Virus production.

Retroviruses from the pMSCV-PIG vector were produced in 293GP packaging cells as
previously described (37). Virus infection was performed in the Bid KO HCT116 cells in the
presence of 10 µg/ml polybrene (American Bioanalytical, AB01643). Puromycin (1 µg/ml) was
added to the cells for 3 days before being removed from the medium. The Puromycin-resistant
pools were cultured and examined for expression of Bid and its mutants. Inducible cell line in
Bid KO HCT116 cells (Bid KO advanced) was made by infecting with virus of pRetroX-Tet-On
Advanced, a vector that expresses rtTA-Advanced, which is a fusion of the Tet repressor
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(TetR) DNA-binding domain, and three transcriptional activation domains from the VP16
protein. The cells were split equally into 2 plates 48 h later and selected by 1 mg/ml G418 for
6 days. The Bid KO advanced cells were then infected with pRetroX-Tight-Pur viruses
containing GFP, tBid-GFP, tBidG94E- GFP and tBidDH6&7-GFP, Bid, BidD60E and BidG94E
cDNAs. The infected cells were then selected by 0.5 µg/ml puromycin for 2 days.
Virus production of pRetroX-Tet-on Advanced, pRetroX-Tight-Pur and pMIG
retroviruses was performed in 293GP packaging cells. pCW57.1 lentivirus was produced in
293T packaging cells.

Approximately 1 x 106 293T cells were transfected with 2 µg

pCW57.1, 1.5 µg of psPAX2 (Addgene #12260), and 0.5 µg of pMD2.G (Addgene #12259) in
a 60 mm plate. Virus was harvested 48 hours post transfection. Virus infection in HCT116
cells was performed using10 µg/ml polybrene (Santa Cruz, NC9840454).

Inducible Viral Gene Expression.

In order to make inducible Tet-on Advance cell lines OctaKO, Octa/Bcl-xl KO, Octa/Mcl1 KO, and Octa/Bax/Bak KO cells were infected with pRetroX-Tet-on Advanced virus in 35
mm plates and plated for single clones in 15 cm plates. Clones were screened for Tet-R
expression via western analysis.

Single clones expressing Tet-R were used for further

experiments. Octa/Mcl-1/Bax KO, Octa/Mcl-1/Bak KO and Octa/Mcl-1/Bax/Bak KO cells were
infected with mpMIG-Tet-R virus in 35 mm plates. Infected pools were sorted for GFP positive
cells. Sorted pools were used for further experiments. 1 x 105 cells of Advanced single clones
or Tet-R sorted pools were subsequently infected with pRetroX-Tight-Pur viruses containing
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the desired gene. Cells were plated and infected in a 35 mm plate using 1:1 ratio of virus and
media and 10 µg/ml of polybrene. Infected pools were then selected with 1 µg/ml of puromycin
for 24-48 hours. Selected pools were used for inducible gene expression assays using 2
µg/ml of Doxycycline.

Genotyping

Genomic DNA was isolated from HCT116 cells using DNeasy Blood and Tissue kit
(Qiagen, 69504), and subjected to polymerase chain reaction to amplify genomic target
regions of interest using Phusion or Taq polymerase (New England Biolabs, E0553S and
M0273L). PCR was performed according to the manufacturer's instructions for each
polymerase, and thermocycler settings were adjusted according to product size and optimal
primer annealing temperatures. PCR products were cloned into the pGEM T-easy vector
(Promega, A1360) using T4 ligase. Following transformation, blue/white selection (Fisher
Scientific, BP4200-10) was used to enrich for colonies containing PCR inserts. Miniprep
DNAs (Wizard Plus SV Minipreps DNA Purification System, Promega, A1460) from the
selected colonies were digested by EcoRI to determine the sizes of inserts. Plasmids with
inserts were then sent for Sanger sequencing using T7 or SP6 primers (UNMC HighThroughput DNA Sequencing and Genotyping Core Facility).
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Sequences of oligos that were cloned into px330/px335 in Chapter 2 are listed in
Table 1. Seoul National University designed and constructed the TALEN expression vector
for Bim, TALEN Library Resource (order # H39213).

siRNA transfection.

Cells in 35-mm culture dishes with antibiotic-free McCoy’s 5A medium+10% fetal
bovine serum and DharmaFECT2 transfection reagent (Dharmacon, Inc., Lafayette, CO,
USA, #T-2002-01) were subjected to siRNA transfection. siRNA Buffer (Dharmacon, Inc.,
#B-002000-UB-100) was used to suspend ON-TARGET Plus siMcl-1, siBcl-xl, or siControl
(Dharmacon, Inc., #L-004501-00, #L-003458-00, #D-001810-10-05) at a final concentration
of 22 nM. Transfected cells were harvested 48–72 h after transfection for western blot
analysis. Sequential transfections were used for double knockdown of Bcl-xl and Mcl-1. The
first transfection in cells was with siBcl-xL or siControl. Cells were split into two separate
plates 48 h later. For the second transfection, one plate was transfected with siControl RNA
and the other with siMCL-1 RNA. Cells subject to double knockdown and the siControl were
harvested for western blot analysis with PARP antibody 24 h after the second transfection.

Apoptosis Assays.

4-5 x 105 cells were seeded in 35 mm plates 16-20 hours prior to apoptosis treatments.
The following reagents were added to plates at the indicated concentrations and durations:
Thapsigargin (3 μM) for 24 h, human recombinant TRAIL (25 ng/ml) for 5 h, ABT-737 (2.5 μM)
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for 16 h, UV (500 J/M2) for 16 h or UV/ABT-737 (500 J/M2-2.5 μM), with ABT-737 (2.5 μM)
added immediately following UV treatment for 16 h. Cells were also subjected to serum
starvation by placing them in McCoy’s 5A media without fetal bovine serum for 48 h. Cells
were analyzed by either FACS or western blot against PARP following each treatment. For
Annexin V analysis, treated cells were gathered from media in plates and trypsinization of
attached cells. Annexin V FITC (Biolegend, San Diego, CA, USA, #640906) was used to stain
treated cells according to the manufacturer's instructions. Each sample was then analyzed for
the FITC signal by flow cytometry. A BD FACSCalibur flow cytometer with BD FACSDiva 8.0
software (UNMC, Flow Cytometry Research Facility) was used for cell counting and
analysis.For detection of PARP cleavage in treated samples, whole cell lysates were prepared
as described above and subjected to western blot with PARP antibody. z-VAD-FMK (40 µM)
was used in the indicated assays to allow for protein expression to be detected by immunoblot.
Quantification of apoptotic cells according to nuclear morphology was carried out as
previously described98. Cells were stained after apoptotic treatment with 1μg/ml Hoechst
33342 (Molecular Probes, H-3570) for 30 min at 37 °C. Pictures were taken for three random
viewing areas containing 400-800 cells for each plate. Two random zones containing 200-300
cells were selected from each viewing area for cell counting. The percentage of cells
undergoing nuclear condensation in each plate was determined by the sum of all zones.
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Mitochondria Staining

Immunostaining was essentially performed as described127. Tom 20 antibody was
added to the paraformaldehyde-fixed cells at 1:200 dilution. The cells were then washed
with PBS and incubated with Alexa Fluor 594-conjugated goat anti-rabbit secondary
antibody (Molecular Probes) at 1:500. Pictures of GFP- positive and immunostained cells
were taken under a Nikon Eclipse 50i fluorescence microscope.

For Mitotracker staining, 2–3 ´ 105 cells were plated in 35-mm plates with a coverslip
at the bottom 24 h prior to staining. Mitotracker (Life Technologies, Inc., M7512) was added
at 20 nM. After an incubation of 15 min, the medium was replaced with PBS. The coverslips
were then placed on slides and sealed. Pictures of GFP-positive and mitotracker-stained
cells were taken under a Nikon Eclipse 50i fluorescence microscope.

CASPASE 3/7 activity assay.

Cells were seeded 48 h prior to treatment in a 96-well plate at a concentration of
approximately 1 × 104 cells per well. 30 μL of Apo-ONE CASPASE 3/7 reagent (Promega, no.
G7790) was added to 50 μL of medium in each well after treatment. Plates were shaken in
the dark for 1 hour to achieve complete cell lysis. Plates were analyzed at 485-nm excitation
and 520 emission with a POLARstar Optima microplate reader (BMG Labtech).
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Bax dimerization assay.

This assay was modified from an assay in a previous study128. Cells were treated with
Doxycycline (2 µg/ml) in the presence of z-VAD-FMK (40 µM) and harvested at the indicated
time points. The harvested cells were then re-suspended in lysis buffer (20 mM HEPES, 10
mM KCl, 1.5 mM MgCl2, 1 mM EDTA, 1 mM EGTA, 1% CHAPS, PH=7.4) with protease
inhibitors (5 mg/ml pepstatin A, 10 mg/ml leupeptin) and 0.1 mM PMSF, and rotated at 4°C
for 1 hour. After centrifugation at 22, 000g for 10 minutes, the supernatant was collected and
split into two halves. BMH (1,6-Bismaleimidohexane, Thermo Fisher Scientific, 22330) was
added to the cell lysates in one half to a final concentration of 0.2 mM and mixed. The lysates
with or without BMH were incubated at room temperature for 1 hour before 4X SDS loading
buffer was added to stop the reaction. The samples were then subjected to SDS-PAGE, and
analyzed by western-blotting with anti-Bax or anti-GFP antibodies.

Statistics.

For statistical analysis, ANOVA: single factor test was used to assess the significance
of mean differences. Differences were considered significant at a P-value of 0.05 or less.
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Discussion and future directions

Discussion:

In this dissertation, we discussed two important questions regarding the role and
working mechanism of certain Bcl-2 family proteins.

In chapter 1, we looked into the mechanism of Bid activation in death receptormediated apoptosis. Bid is known as a critical mediator of the mitochondrial pathway of
apoptosis following death receptor activation. However, since full-length Bid possesses potent
apoptotic activity, the role of a caspase mediated Bid cleavage is not established in vivo. In
addition, due to the fact that multiple caspases cleave Bid at the same site in vitro, the identity
of the Bid-cleaving caspase during death receptor signaling remains uncertain. Moreover, as
Bid maintains its overall structure following its cleavage by caspase 8, it remains unclear how
Bid is activated upon cleavage. We examined these two critical points by generating Bid KO
colon cancer cells and reconstituting with wild-type or mutants of Bid. While the loss of Bid
blocked apoptosis following TRAIL treatment, this blockade was relieved by the reintroduction of the wild-type Bid. In contrast, the caspase resistant mutant BidD60E and a BH3
defective mutant BidG94E failed to restore TRAIL-induced apoptosis. By generating
Bid/Bax/Bak TKO cells, we demonstrated that Bid is primarily cleaved by caspase 8, not by
effector caspases, to give rise to tBid upon TRAIL treatment. Importantly, despite the presence
of an intact BH3 domain, a tBid mutant lacking the mitochondrial targeting helices (a6 and a7)
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showed diminished apoptotic activity. Together, these results for the first time establish that
cleavage by caspase 8 and the subsequent association with the outer mitochondrial
membrane are two critical events that activate Bid during death receptor-mediated apoptosis.

In chapters 2&3, we dealt with a long-lasting question in apoptosis research: how do
BH3-only proteins activate Bax/Bak to induce apoptosis? Although all pro-apoptotic BH3-only
proteins are known to bind/neutralize the anti-apoptotic Bcl-2 proteins, Bid (tBid), Bim, and
Puma, and even other BH3-only proteins except Bad, possess an additional activity of directly
activating Bax/Bak in vitro. This latter activity has been proposed to be responsible for
triggering Bax/Bak activation following apoptotic stimulation. To test whether this is really how
BH3-only proteins work to induce Bax/Bak activation, we carried out a two-step study.

First, we examined whether direct activators are required for Bax/Bak activation and
MOMP.

We

generated

Bid-/-/Bim-/-/Puma-/-

TKO,

TKO/Bax-/-/Bak-/-

(PentaKO),

and

PentaKO/Mcl-1-/- (HexaKO) HCT116 cells through gene editing. Surprisingly, although the
TKO cells were resistant to several apoptotic stimuli, robust apoptosis was induced upon the
simultaneous inactivation of Bcl-xL and Mcl-1, two anti-apoptotic Bcl-2 proteins known to
suppress Bax/Bak activation and activity. Importantly, such apoptotic activity was completely
abolished in the PentaKO cells. In addition, ABT-737, a BH3 mimetic that inhibits Bcl-xL/Bclw/Bcl-2, induced Bax activation in HexaKO cells reconstituted with endogenous level of GFPBax. Further, by generating TKO/p53-/- (QKO) cells, we demonstrated that p53, a tumor
suppressor postulated to directly activate Bax, is not required for Bid/Bim/Puma-independent
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Bax/Bak activation. Together, these results strongly suggest that the direct activation activities
of Bid (tBid), Bim, Puma, and p53 are not essential for activating Bax/Bak once the antiapoptotic Bcl-2 proteins are neutralized.

In another work carried out by our group118, we went further to knock out all eight BH3only proteins (OctaKO), and eventually, all the 17 members of the Bcl-2 family (Bcl-2 AllKO).
We found that once Bcl-xL and Mcl-1 are inhibited or neutralized, the OctaKO and Bcl-2 AllKO
cells can go through Bax/Bak induced apoptosis. This indicated that the direct activation
activity is not required for Bax/Bak activation during apoptosis.
Second, we investigated whether direct activation have any contribution to Bax/Bak
activation. While not required, the direct activators might still be able to accelerate the process
of Bax/Bak activation. By inducing the expression of the BH3-only proteins in OctaKO and its
derivatives, Octa/Mcl-1 KO and OCTA/Bcl-xL KO cells, we identified Bcl-xL and Mcl-1, instead
of Bax and Bak, are the functional targets of the BH3-only proteins. BH3-only proteins neither
have any selectivity between Bax and Bak, nor can they accelerate Bax/Bak activation when
the anti-apoptotic proteins are eliminated. The Bid mutants that have no direct activation
activity can fully reconstitute the death receptor induced apoptotic pathway. Taken together,
our date indicated that the BH3-only proteins induce apoptosis by targeting Bcl-xL and Mcl-1,
allowing the membrane mediated activation of Bax/Bak.
Although OctaKO and Bcl-2 allKO cells provide the necessary genetic background to
understand the seemingly complex functional relationship among the Bcl-2 family proteins, it
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is worth pointing out that our conclusions are based on genetic experiments carried out in
HCT116 cells. Theoretically, it remains possible that in other cellular contexts, direct activation
may play a positive role in Bax/Bak activation. However, such a role can only be tested in a
cellular environment without the interference and complication from other BH3-only proteins.

Future directions:

How do Bcl-xL and Mcl-1 protect the cells against Bax/Bak?

According to the previous models, there are different interpretations of how Bcl-xL and
Mcl-1 protect cells from apoptosis. The “direct activation” model claimed that anti-apoptotic
proteins inhibit Bax/Bak through sequestering the direct activators. Our results are against
this theory, as the elimination of direct activators is not adequate to block Bax/Bak dependent
apoptosis. On the other hand, the “neutralization” model suggested that the inhibition of
Bax/Bak by pro-survival Bcl-2 proteins is through the direct binding of Bcl-xL/Mcl-1 to Bax/Bak.
This hypothesis also has its deficiency, as it cannot explain the cytosolic localization of Bax
under normal condition. The “retrotranslocation” hypothesis seemingly provided an
explanation, but there is still not enough evidence to support it. Also, the different localization
of Bax and Bak in the cells indicated that there might be distinct mechanisms for the inhibition
of Bax and Bak. The Bcl-2 ALLKO cells provided us a valuable background to study the
interaction between antiapoptotic Bcl-xL/Mcl-1 and Bax/Bak. Uncovering the mechanism of
Bax/Bak inhibition by Bcl-xL/Mcl-1 is crucial for us to better understand the regulation of
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apoptosis, and might give us new insights into the therapies for diseases related to dysfunction
of Bcl-2 family proteins.

TABLE 1. Sequences of sgRNA and the vectors in Chapter 2.
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TABLE 2. Primers used for genomic sequencing.
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TABLE 3. Knock-out cell lines generated in Chapter 2.
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Table S1. Muta ons in the targeted loci of KO cell lines.

Cell Name

Gene

Clone#

“2+5” KO

BAX

2

Parental Clone

Octa/MCL-1/BAX KO

A1
BAX

1

Octa/MCL-1 KO #10

Exon
targeted
4
4
5
5
1
1
1
3
1
1
1
4

Octa/MCL-1/BAK KO

BAK

30

Octa/MCL-1 KO #10

5

1, 2

1 bp inser on

Octa/BCL-xL KO

BCL-xL

5

OctaKO # 8

1
1

1
2

313 bp inser on w/ stop codon
330 bp inser on w/ stop codon

BAK
BCL-xL
BCL-2
BCL-w
MCL-1

Edited
alleles
1
2
1
2
1, 2
1
2
1,2
1
2
1, 2
1, 2

1 bp inser on
2 bp inser on
1 bp inser on
465 bp inser on, w/ stop codon
238 bp inser on
2 bp inser on
1 bp dele on
9 bp dele on
14 bp dele on
742 bp inser on
1 bp inser on
1 bp dele on

Table 4. Mutations in the targeted locus of KO cell lines in chapter 3.

Muta ons
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Supplemental data 1: DNA constructs used in the study
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Supplemental data 2: knock-out cell lines used in the study

Cell line name

Gene(s) knocked out

Parental cell line

Method

Chapter

Bid KO

Bid

HCT116

TALEN

1

Bid/Bax/Bak TKO

Bid, Bax, Bak

Bid KO

CRISPR

1

Bid/Bim/Puma TKO

Bid, Bim, Puma

HCT116

TALEN, Nickase

2

PentaKO

Bid, Bim, Puma, Bax, Bak

Bid/Bim/Puma TKO

CRISPR

2

HexaKO

PentaKO + Mcl-1

PentaKO

CRISPR

2

QKO

Bid, Bim, Puma, p53

Bid/Bim/Puma TKO

CRISPR

2

OctaKO

all eight BH3-only proteins

HCT116

CRISPR

3
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OctaKO + Mcl-1
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CRISPR

3

Octa/Bcl-xL KO

OctaKO + Bcl-xL
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CRISPR

3
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CRISPR

3
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OctaKO + Mcl-1 + Bax

Octa/Mcl-1 KO

CRISPR

3
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CRISPR

3

OctaKO + Mcl-1 + Bax + Bak

Octa/Mcl-1 KO

CRISPR

3

HCT116

CRISPR

3

OctaKO

CRISPR

3

Octa/Mcl-1/Bax/Bak
KO
Bax, Bak, anti-apoptotic Bcl-2
"2+5" KO
proteins
Bcl-2 AllKO

all 17 Bcl-2 family proteins

Supplemental data 3: expression cell lines used in the study
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stable expression

stable expression 2

inducible expression
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1
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1
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1
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2

HexaKO

pMIG-GFP-Bax

2
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3
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pRetro-adv

pRetro-tBid-G9H

3
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pRxXE-9HGFP-Bim

3
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pRetro-adv

pRetro-9HGFP-Puma

3

OctaKO

pRetro-adv

pRetro-9HGFP-Noxa

3
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pRetro-adv
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3
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pRetro-adv

pRetro-6HGFP-Bmf

3
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3
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3
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3
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3
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pRetro-adv

pRetro-GFP

3
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pRetro-adv
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3
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pRetro-adv

pRxXE-9HGFP-Bim

3
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pRetro-adv
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3
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pRetro-adv

pRetro-9HGFP-Noxa

3
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pRetro-adv

pRetro-9HGFP-Bad3SA

3

Octa/Mcl-1 KO

pRetro-adv

pRetro-6HGFP-Bmf

3

Octa/Mcl-1 KO

pRetro-adv

pRetro-9HGFP-Bik

3

Octa/Mcl-1 KO

pRetro-adv
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3
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pRetro-adv
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3

GFP/BadBH3
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3
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3
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pRetro-adv
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3
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pRetro-adv

pRetro-tBid-G9H

3

Octa/Bcl-xL KO

pRetro-adv

pRxXE-9HGFP-Bim

3

Octa/Bcl-xL KO

pRetro-adv

pRetro-9HGFP-Puma

3

Octa/Bcl-xL KO

pRetro-adv

pRetro-9HGFP-Noxa

3

Octa/Bcl-xL KO

pRetro-adv

pRetro-9HGFP-Bad3SA

3
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Octa/Bcl-xL KO

pRetro-adv

pRetro-6HGFP-Bmf

3

Octa/Bcl-xL KO

pRetro-adv

pRetro-9HGFP-Bik

3

Octa/Bcl-xL KO

pRetro-adv

pRetro-6HGFP-Hrk

3

Octa/Bax/Bak KO

pRetro-adv

pRetro-GFP

3

Octa/Bax/Bak KO

pRetro-adv

pRetro-tBid-G9H

3

Octa/Bax/Bak KO

pRetro-adv

pRxXE-9HGFP-Bim

3

Octa/Bax/Bak KO

pRetro-adv

pRetro-9HGFP-Puma

3

Octa/Bax/Bak KO

pRetro-adv

pRetro-9HGFP-Noxa

3

Octa/Bax/Bak KO

pRetro-adv

pRetro-9HGFP-Bad3SA

3

Octa/Bax/Bak KO

pRetro-adv

pRetro-6HGFP-Bmf

3

Octa/Bax/Bak KO

pRetro-adv

pRetro-9HGFP-Bik

3

Octa/Bax/Bak KO

pRetro-adv

pRetro-6HGFP-Hrk

3

OctaKO

pRetro-adv

mpMIG-Fl-Noxa

pRetro-9HGFP-Bad3SA

3

OctaKO

pRetro-adv

mpMIG-Fl-

pRetro-9HGFP-Bad3SA

3

NoxaL29E
Octa/Bax/Bak KO

pRetro-adv

mpMIG-Fl-Noxa

pRetro-9HGFP-Bad3SA

3

Octa/Bax/Bak KO

pRetro-adv

mpMIG-Fl-

pRetro-9HGFP-Bad3SA

3

NoxaL29E
Octa/Mcl-0/Bax KO

mpMIG-Tet-R

pRetro-GFP

3

Octa/Mcl-1/Bax KO

mpMIG-Tet-R

pRetro-tBidGFP

3
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Octa/Mcl-1/Bax KO

mpMIG-Tet-R

pRxXE-9HGFP-Bim

3

Octa/Mcl-1/Bax KO

mpMIG-Tet-R

pRetro-9HGFP-Bad3SA

3

Octa/Mcl-1/Bak KO

mpMIG-Tet-R

pRetro-GFP

3

Octa/Mcl-1/Bak KO

mpMIG-Tet-R

pRetro-tBidGFP

3

Octa/Mcl-1/Bak KO

mpMIG-Tet-R

pRxXE-9HGFP-Bim

3

Octa/Mcl-1/Bak KO

mpMIG-Tet-R

pRetro-9HGFP-Bad3SA

3

Octa/Mcl-1/Bax/Bak KO

mpMIG-Tet-R

pRetro-GFP

3

Octa/Mcl-1/Bax/Bak KO

mpMIG-Tet-R

pRetro-tBidGFP

3

Octa/Mcl-1/Bax/Bak KO

mpMIG-Tet-R

pRxXE-9HGFP-Bim

3

Octa/Mcl-1/Bax/Bak KO

mpMIG-Tet-R

pRetro-9HGFP-Bad3SA

3

Octa/Bax/Bak KO

pMIG-GFP-Bax

pRetro-GFP

3

Octa/Bax/Bak KO

pMIG-GFP-Bax

pRetro-tBid-Fl

3

Octa/Bax/Bak KO

pMIG-GFP-Bax

pRxXE-9HGFP-Bim

3

Octa/Bax/Bak KO

pMIG-GFP-Bak

pRetro-GFP

3

Octa/Bax/Bak KO

pMIG-GFP-Bak

pRetro-tBid-Fl

3

Octa/Bax/Bak KO

pMIG-GFP-Bak

pRxXE-9HGFP-Bim

3

"2+5" KO

pCW-GFP-Bax

3

"2+5" KO

pCW-GFP-BaxΔC21

3

Bcl2 AllKO

pCW-GFP-Bax

3

Bcl2 AllKO

pCW-GFP-BaxΔC21

3
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Bcl2 AllKO

pMIG-GFP

pCW-GFP-Bax

3

Bcl2 AllKO

pMIG-tBid-GFP

pCW-GFP-Bax

3

Bcl2 AllKO

pMIG-GFP-Bim

pCW-GFP-Bax

3

Bcl2 AllKO

pMIG-GFP-Bad3SA

pCW-GFP-Bax

3

Bcl2 AllKO

pMIG-Bcl-xL

pMIG-GFP

pCW-GFP-Bax

3

Bcl2 AllKO

pMIG-Bcl-xL

pMIG-tBid-GFP

pCW-GFP-Bax

3

Bcl2 AllKO

pMIG-Bcl-xL

pMIG-GFP-Bim

pCW-GFP-Bax

3

Bcl2 AllKO

pMIG-Bcl-xL

pMIG-GFP-Bad3SA

pCW-GFP-Bax

3

Bcl2 AllKO

pMIG-GFP

pCW-GFP-BaxΔC21

3

Bcl2 AllKO

pMIG-tBid-GFP

pCW-GFP-BaxΔC21

3

Bcl2 AllKO

pMIG-GFP-Bim

pCW-GFP-BaxΔC21

3

Bcl2 AllKO

pMIG-GFP-Bad3SA

pCW-GFP-BaxΔC21

3

Bcl2 AllKO

pMIG-Bcl-xL

pMIG-GFP

pCW-GFP-BaxΔC21

3

Bcl2 AllKO

pMIG-Bcl-xL

pMIG-tBid-GFP

pCW-GFP-BaxΔC21

3

Bcl2 AllKO

pMIG-Bcl-xL

pMIG-GFP-Bim

pCW-GFP-BaxΔC21

3

Bcl2 AllKO

pMIG-Bcl-xL

pMIG-GFP-Bad3SA

pCW-GFP-BaxΔC21

3

OctaKO

mpMIG

3

OctaKO

mpMIG-Bid

3

OctaKO

mpMIG-BidG94E

3

OctaKO

mpMIG-BidI82/83A

3
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OctaKO

mpMIG-

3

Bid/BadBH3
Octa/Mcl-1 KO

mpMIG

3

Octa/Mcl-1 KO

mpMIG-Bid

3

Octa/Mcl-1 KO

mpMIG-BidG94E

3

Octa/Mcl-1 KO

mpMIG-BidI82/83A

3

Octa/Mcl-1 KO

mpMIG-

3

Bid/BadBH3

